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Course Overview
This year’s 17th Annual Fred Scott Feline Symposium will educate and update veterinarians in the latest 
developments in feline dermatology, systemic hypertension, renal disease, liver and pancreatic disorder, 
and nutrition, including nutritional management of sick cats.
Accreditation and Continuing Education Credit
The College of Veterinary Medicine at Cornell University accredits this symposium for a maximum of 16 
hours of continuing education credit. Each attendee should claim only those hours of credit that he/she 
actually spends in the educational lectures. You are asked to sign-in at the registration desk on the first 
day so that there is evidence of your attendance.
For questions about accreditation and continuing education credit please contact:
Office of Continuing Education Phone 607-253-3200
College of Veterinary Medicine Fax 607-253-3198
Box 52, T1 002 VRT Email CVMERM@cornell.edu
Cornell University Website www.vet.cornell.edu/extension/conedu
Ithaca, NY 14853-6401
Evaluation
It is important for the Cornell Office of Continuing Education, faculty, corporate sponsors, and exhibitors to 
receive your feedback. We ask that you complete the evaluation form and return it to the registration desk 
before you leave the symposium. The information you provide us is essential in the development of future 
educational programs. We welcome and encourage your comments on all aspects of this symposium.
Certificate of Participation
You will receive a certificate of participation, which will be available at the registration desk during lunch 
on Saturday, July 30. The certificate verifies your attendance at the 17th Annual Fred Scott Feline 
Symposium.
Meals
Meal tickets are in the back of your nametag for:
• Lunch on Friday and Saturday. These lunch meal tickets are to be turned into the cafeteria 
cashier after you select your lunch on Friday, and at the cafeteria entrance on Saturday.
• Lunch with Dr. Zoran: If you signed up to have lunch with Dr. Zoran on Saturday please turn in 
your ticket to the staff member at the meeting room entrance.
Tours
If you registered to participate in a tour of the college during lunch on Friday or Saturday you will find an 
admittance ticket in the back of your nametag.
Course Materials
The course materials that are distributed during this symposium are under the auspices of the Office of 
Continuing Education at the College of Veterinary Medicine at Cornell University. Duplication of these 
materials is prohibited.
Disclaimer
The lectures offered during this symposium will include some discussion of off-label use and commercial 
products and/or services. The opinion and recommendations expressed by the faculty are their own.
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•  All lectures will be held in Lecture Hall I in the Veterinary Education Center.
•  Continental Breakfasts and breaks will be located in the Atrium.
Friday, July 29, 2005
7:30 - 8:00 am
8 :0 0 -8 :1 5
Registration
Continental Breakfast 
Sp o n so red  b y  ID EXX Laboratories
Welcome - Ja m es Richards, DVM
James Law Lobby
8 :1 5 -9 :1 5
9 :1 5 -9 :3 0
9 :3 0 -10 :30
10:30 -10:45
10:45 -11:45
11:45-1:15 pm
1:1 5 -2 :1 5
2 :1 5 -2 :3 0
2 :3 0 -3 :3 0
3 :3 0 -3 :4 5
3 :4 5 -5 :1 5
6 :3 0 -9 :0 0
Dermatology
D anny Scott, DVM  
S p o n so red  b y  Vetoquinoi USA
Feline Dermatology Part I
Break
Feline Dermatology Part I (cont’d) 
Break
Feline Dermatology Part I (cont’d) 
Lunch
Feline Dermatology Part II 
Break
Feline Dermatology Part II (cont'd) 
Break
Feline Dermatology Part II (cont’d) 
Annual Picnic
Cafeteria
Baker Institute
Saturday, July 30, 2005
7:30 - 8:00 am Continental Breakfast
S po n so red  b y  Merial
8:00 - 9:00 Feline Pancreatitis I
D ebra Zoran, DVM, PhD
9 :0 0 -9 :1 5  Break
9 :1 5 -1 0 :1 5  Feline Pancreatitis II
D ebra Zoran, DVM, PhD
1 0 :15 -1 0 :3 0  Break
10:30 - 11:30 Inflammatory Liver Disease in Cats
D ebra Zoran, DVM, PhD
11:30- 1:00 pm Lunch
Sp o n so red  b y  Schering-P lough A nim al H ealth
1:00 - 2:00 Staged Management of Feline Chronic Kidney Disease
S co tt Brown, VMD, PhD  
Sp o n so red  b y  H eska Corporation
2 :0 0 -2 :1 5  Break
2 :1 5 -3 :1 5  Proteinuria and Microalbuminuria: Much Ado about What?
S co tt Brown, VMD, PhD
3 :1 5 -3 :3 0  Break
3:30 - 5:00 The Renal - Hyperthyroid Connection
S co tt Brown, VMD, PhD
Sunday, July 31, 2005
8:00 - 8:30 am Continental Breakfast
Sponsored  b y  The lam s C om pany
8:30 - 10:00 Diagnosis and Treatment of Feline Systemic Hypertension
S co tt Brown, VMD, PhD
10:00 -10 :1 5  Break
10:15 -11 :45  Feeding Cats: Obesity, IBD, and the Carnivore Connection in Cats
Debra Zoran, DVM, PhD
Cafeteria
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C o r p o r a t e  S p o n s o r s
Heska Corporation
www.heska.com
Heska Corporation, headquartered in Fort Collins, Colorado, was founded in 1988. Our passion is to 
create and deliver innovative, high-value products and services to benefit the health and well being of 
companion animals. We are driven by our respect for the human-animal bond and to that end we apply 
anirl^iTh ^  technolo9ies and veterinary expertise to solve important problems related to companion 
. ea eska markets a broad line of pharmaceuticals, vaccines and diagnostic products, as well 
ins ruments, reagents and services for the diagnosis and monitoring of companion animal health.
Schering - Plough Animal Health
www.spah.com
For mor6 than 40 years, Schering-Plough Animal Health has provided some of the world's best-known 
animal health products. Their global animal health business comprises a range of pharmaceuticals, 
biologicals and parasiticides for food-producing and companion animals. As a result of their commitment 
to excellence in this area, Schering Plough ranks sixth largest in world animal health markets.
VetQQuinol USA
For nearly 80 years the Vetoquinol group has been dedicated to animal health and the veterinary 
surgeons that work in it. As a result of its own research and in collaboration with partners, Vetoquinol 
regularly provides new and innovative products to the profession. Now the 14th largest veterinary 
company in the world, we continue to seek solutions to the problems in veterinary practice.
The lams Cgmpanv
www.iams.com
The mission of The lams Company is to enhance the well-being of dogs and cats by providing world-class 
quality foods and pet care products. The lams team of nutritionists, veterinarians and food scientists at the 
Paul F. lams Technical Center conducts controlled feeding studies to enhance the well being of dogs and 
cats.
IDEXX Labgratgries. Inc.
www.idexx.com
More than 50,000 veterinary clinics worldwide rely on IDEXX products and services to help pets live 
longer, healthier, happier lives. They provide veterinarians with the diagnostic products and services, 
information technology, and pharmaceuticals needed to practice the best medicine possible for animals 
under their care.
MERIAL
www.merial.com
Merial is a world-leading animal health company. W e are a forward-looking company with a proven track 
record, producing pharmaceutical products and vaccines for livestock, pets and wildlife. W e are on the 
cutting edge of product development and innovation, providing millions of doses worldwide annually to 
keep livestock and pets healthy.
Annual Picnic
Hazlitt 1852 Vineyards, Inc., a part of the Fingerlakes Wine Trail, generously donated the wine provided at 
the Feline Symposium Annual Picnic.
E x h i b i t o r s
Banfield, The Pet Hospital 
Blackwell Publishing/Teton New Media 
Cornell Feline Health Center 
Cornell Diagnostic Laboratory 
Eklin Medical Systems, Inc.
Flexible Footwear Company 
Heska Corporation 
Hill’s Pet Nutrition, Inc.
The lams Company 
Lippincott Williams & Wilkins 
Mosby/Saunders 
Purr...fect Fence
Schering - Plough Animal Health 
Universal Ultrasound 
Vetoquinol USA
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Scott A. Brown. VMD. PhD. Diplomate ACVIM
Scott Brown received his veterinary degree in 1982 from the University of Pennsylvania. He 
completed an internship and residency in Small Animal Internal Medicine at the Teaching Hospital of 
the University of Georgia in 1986 and received Board Certification in Internal Medicine in 1987. From 
1984-1989, Dr. Brown received a PhD in Renal Pathophysiology from the University of Georgia and 
was a post-doctoral research fellow at the University of Alabama-at-Birmingham School of Medicine. 
Since 1989, he has been a faculty member of the University of Georgia with a joint appointment in 
the Departments of Physiology and Small Animal Medicine where is currently a Professor of 
Physiology. He is presently the Acting Associate Dean for Academic Affairs. Dr. Brown has been 
recognized for excellence in research and teaching, having received numerous awards including the 
AVMA Excellence in Research Award and the National Norden Distinguished Teacher Award. His 
research interests are progression of chronic kidney disease and systemic hypertension.
Josiah Meigs Distinguished Professor Phone 706-542-5857
Department of Physiology & Pharmacology 706-542-3014
University of Georgia Fax 706-542-3015
College of Veterinary Medicine E-mail sbrown@vet.uga.edu
1 D. W. Brooks Drive 
Athens, GA 30602
Danny Scott. DVM, Diplomate ACVD
Danny Scott is a 1971 graduate of the University of California, Davis, and is presently Professor of 
Dermatology and Co-chief of the Dermatology Service at Cornell University. Dr. Scott’s activities 
include teaching (students, interns, and residents), clinical service, diagnostic dermatopathology, 
clinical research, consultation service, and committee work. He is the author or co-author of over 490 
publications and has presented over 340 continuing education seminars around the world.
College of Veterinary Medicine
Department of Clinical Sciences Phone 607-253-3029
Box 34, T3 002D Veterinary Research Tower Fax 607-253-3534
Cornell University E-mail dws11@cornell.edu
Ithaca, NY 14853-6401
Debra L Zoran. DVM. PhD. Diplomate. ACVIM
Dr. Zoran graduated from the Kansas State University, College of Veterinary Medicine in 1984 and 
became a Diplomate of the American College of Veterinary Internal Medicine in 1993. She received 
her PhD in Nutrition from Texas A&M University where she became an assistant clinical professor in 
1997. Dr. Zoran is currently a clinical associate professor at Texas A&M University and her research 
interests include gastroenterology, small animal (feline) nutrition, and nutritional management of 
inflammatory and allergic intestinal diseases. She has presented at over 25 regional and national 
meetings since 2001.
Clinical Associate Professor
Dept, of Small Animal Medicine and Surgery
College of Veterinary Medicine
Texas A&M University
College Station, TX 77843-4474
Phone (979) 845-2351 
Fax (979) 845-6978  
E-mail Dzoran@cvm.tamu.edu
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Eileen Adamo, DVM  
The Cat Doctors 
Penfield NY 14526
Terry Allen, DVM  
Clark Animal Care Center 
Penfield NY 14526
Elizabeth Bales, VMD  
The Chestnut Hill Cat Clinic 
Jenkintown PA 19046
Robert Bebko, VMD  
Cat Clinic
Pittsburgh PA 15224
Holly Blair, DVM  
Suburban Animal Hospital 
Gainesville FL 32607
Amy Brenner, DVM 
Gateway Animal Hospital 
Wayne PA 19087
Eve Brown, DVM  
Meadowridge Veterinary Clinic 
Lansing NY 14882
Cherie Buisson, DVM  
All Cats Hospital 
Largo FL 33774
William Cadwallader, DVM  
Homer and Tully Animal Clinic 
Homer NY 13077
Michael Casale, DVM  
Canandaigua Veterinary Hospital 
Palmyra NY 14522
Carol Castro, VMD  
Collegeville Cat Clinic 
Collegeville PA 19426
Daniel Cirnigliaro, DVM  
Wholpet Health Center, Inc. 
Malden MA 02148
Ashley Cooper 
Allegany NY 14706
Alice Marie Donnelly, DVM  
Freeville NY 13068
Beth Alden, DVM 
Kingston Animal Hospital 
Hurley NY 12443
Betsy Arnold, DVM  
Caring for Cats 
Rochester NY 14612
Bridget Barry, DVM  
Slaterville Springs NY 14881
Jan Belmonte, DVM  
Bolton MA 01740
Louis Borgia
Clarks Summit PA 18411
Kevin Britt, DVM  
Veterinarians To Cats 
Roanoke VA 24018
Catherine Buck, VMD
D. Charles E. London DVM PC 
Red Lion PA 17356
Colin Bullmore, DVM  
Hamlin Veterinary Clinic 
Moscow PA 18444
Robert Carlson, DVM  
The Cat Doctor 
Bedford MA 01730
Donald Caslow, VMD
East Suburban Animal Hospital
Murrysville PA 15668
Amy Denise Charpentier, DVM  
Clark Animal Care Center 
Penfield NY 14526
Jean Clark, DVM
Cat Hospital of Mississauga
Mississauga Ontario L5C 2S3
Jeffrey Di Mayo, DVM  
Clarence NY 14031
James Dorney, DVM  
Summit Dog & Cat Hospital 
Summit NJ 07901
Lorri Dring, DVM  
Just Cats Health Care 
East Setauket NY 11733
Blair Ebert, DVM  
Housecalls for Cats 
Garden City NY 11530
Janette Ellison, DVM
The Cat Hospital of Fairfax Inc
Fairfax VA 22030
Andrew Erickson, VMD  
Olde Bedford Veterinary Clinic 
Bedford PA 15522
Jennifer Fligiel, DVM
Cats Exclusively Veterinary Center
Seattle WA 98133
Rachel Gardner, DVM  
Cat Care Clinic 
Green Bay Wl 54302
Julie Giles, DVM  
Union Veterinary Clinic 
Washington DC 20002
Susan Gordon-Garcia, DVM  
La Plata MD 20646
David Hagan, DVM  
Waynesboro PA 17268
Sasha Hilchuck, VMD  
Brooklyn NY 11215
Adrianna Hordinsky 
Summit Dog & Cat Hospital 
Summit NJ 07901
Robert Jacobson, DVM  
Countryside Vet Clinic 
Dryden NY 13053
Kimberly Kal-Downs, DVM  
Liberty Research Inc. 
Waverly NY 14892
Marilyn Komarnisky, DVM  
Glenora Cat Clinic 
Edmonton Alberta T5M 4A8
Nancy J. Dunkle, DVM  
Exclusively Cats Veterinary Hospital 
Medford NV 08055
Elizabeth Eilers, DVM  
Cat Clinic of Greensboro 
Greensboro NC 27418
Amy Engle, DVM
Tampa Bay Vet Emergency Services 
Largo FL 33771
Lynda Ewald, DVM  
Cat Hospital of Chicago 
Chicago IL 60618
Vicki Fowler, DVM  
Wynantskill NY 12198
Laura George, DVM
Catnip & Carrots Animal Hospital
New Hyde Park NY 11040
Francis Goldsmith, DVM  
Rancho Bernaakdo Vet Clinic 
SanDiego CA 92128
Cindy Haas, DVM  
Cat Clinic
Knoxville TN 37922
Gerryll Hall, DVM  
Schering-Plough Animal Health 
Lawrenceville GA 30043
Amy Hinc, VMD
Cosmic Cat Veterinary Clinic
New Haven CT 06512
Andrea Jacobson, DVM  
Country Cats
Croton-on-Hudson NY 10520
Darryl Jang, DVM  
Blackstone Valley Vet Hospital 
Uxbridge MA 01748
Nicole Kayser-Laundry, DVM  
.Chittenango Animal Hospital 
DeRuyter NY 13052
Lisa Koob, DVM  
Cat Clinic
Knoxville TN 37922
Participants
Cathy Kreis, DVM  
Jacksonville NC 28546
Joan Lee, DVM
Brockway Veterinary Hospital, PC 
Brockway PA 15824
James Mac Donald, DVM  
Red Hook Veterinary Hospital 
Red Hook NY 12571
Tom Mann, DVM
Akron Peninsula Veterinary Office 
Akron OH 44313
Morag McMurray, DVM  
Harrowsmith On KH 1VO
Sylvie Nicholson, DVM  
Merivale Cat Hospital 
Ottawa Ontario K1L 5C1
Alice Jayne Payton, DVM  
Cranbury NJ 08512
Annette Poirier, CVT  
All Cats Hospital 
Largo FL 33774
William Rabon, DVM  
Southport Animal Hospital 
Southport NC 28461
Tom Rothwell, DVM  
Paris Hill Cat Hospital 
Paris NY 13456
Neal Saslow, DVM  
Baldwin Animal Hosp 
Huntington NY 11743
Linda Schoenberg, VMD  
Just Cats Hospital 
South Euclid OH 44121
Keith Scudder
Rio Vista Vet Hospital
Painted Post NY 14870
Gay Senk, DVM  
Brookville NY 11545
Marguerite Staderman, DVM  
All Cats Care Center 
Webster NY 14580
Lana Kuenzi, DVM  
Kuenzi Family Pet Hospital 
Waukesha W l 53189
Leann Lydon 
Ramsey NJ 07446
Troy Majure, DVM  
Animal Medical Center 
Clinton MS 39056
Katie McClaine, DVM
Cats Limited Veterinary Hospital
West Hartford CT 06107
Laura Meaux, DVM  
Cat Hospital of Metairie 
Metairie LA 70005
Susan O'Neill, DVM  
Auburn MA 01501
Susan Petro, DVM  
Monroe NY 10950
Steven Price, DVM  
Watertown Animal Hospital PC 
Watertown CT 06795
Ilona Rodan, DVM  
Cat Care Clinic 
Madison W l 53705
Eve Ryan, DVM
Cat Care Center
North Syracuse NY 13212
Jennifer Saver, DVM
Catnip & Carrots Animal Hospital
New Hyde Park NY 11040
James Schulke, DVM  
Santa Monica CA 90403
Jon Seguire, DVM
Exclusively Cats Veterinary Hospital
Winnipeg Manitoba R3M 0W8
Susan Shumaker, DVM  
Branchport NY 14418
Michelle Stanek, DVM  
Seneca Animal Hospital P C 
East Aurora NY 14052
Participants
Heather Stewart, DVM  
Guildcrest Cat Hospital 
Scarborough Ont M1N 1V3
Kathryn Stoltzfus, BVSc 
Windcrest Animal Hospital 
Boothwyn PA 19061
Cynthia Swingle, VMD  
St Lawrence Valley Vet Clinic 
Massena NY 13662
Susan Thomas, DVM  
The Cat Hospital 
Toronto ON M2N 4R6
Suzanne Trosclair, DVM  
Civic Feline Clinic 
Walnut Creek CA 94596
Nancy Vigil
The Visiting Veterinarians 
Warrenville IL 60555
Kathleen Wakefield, DVM  
Clark Animal Care Center 
Penfield NY 14526
Gary West, DVM  
Oklahoma City Zoo 
Edmond OK 73034
Gry Wildenstein, DVM  
Adana Veterinary Clinic 
Freeville NY 13068
Tane Wiseman, DVM  
Haskell Valley Vet Clinic 
Portville NY 14770
Netta Zahavi, DVM  
Suburban Animal Hospital 
Rochester NY 14623
Catherine Stiner, DVM  
Bloomfield Animal Hospital 
Bloomfield NY 14469
Eliza Sundahl, DVM  
KC Cat Clinic 
Kansas City MO 64114
Kristina Szabo, DVM  
Guildcrest Cat Hospital 
Scarborough Ontario M1N 1V3
Jean Townsend, VMD  
Jean B. Townsend, VM D  
Lutherville MD 21093-6307
Ed Tudor, DVM
Paradise Island Animal Hospital 
Saipan MP 96950
Aaron Vigil, DVM  
Warenville IL 60555
Carla Walsh, DVM  
Lansingburgh Vet Hospital 
Clifton Park NY 12065
Teri White, DVM  
Community Animal Hospital 
Easton MD 21601
Deb Williams, DVM  
Jamestown Veterinary Clinic 
Kinsman OH 44428
Debbie Wismer, DVM  
Millersville PA 17551
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Feline D erm atology: A re We C onfused Yet?
Danny W. Scott, DVM, Diplomate, ACVD 
Department o f Clinical Sciences 
College o f Veterinary Medicine, Cornell University 
Ithaca, NY
STAPHYLOCOCCAL SKIN DISEASE
Staphylococcal skin disease is said to be uncommon to rare in cats. I believe it is more 
common than we think.
Early studies indicated that S. simulans was the most commonly isolated coagulase- 
negative Staphylococcus from normal cats, and could be considered a normal resident.1 Recent 
studies indicate that this organism was actually S.felis (S.felis differs from S. simulans in that it 
ferments mannose, produces a strong alkaline phosphatase reaction, and is susceptible to 
bacitracin).2 In like fashion, early studies indicated that S. aureus was the common coagulase- 
positive Staphylococcus isolated from cats .1 Recent studies indicate that this organism was 
actually S. intermedins (formerly biotypes E and F o f S. aureus) 2
Both S. intermedins and S. fehs are isolated from cats with skin disease.'-2 As these 
organisms are not particularly virulent, any staphylococcal infection is presumably secondary to 
some cutaneous, metabolic, or immunologic abnormality. Cats with the following dermatoses 
should be examined for the presence o f staphylococci: “resistant acne”; “resistant ringworm”; 
“resistant eosinophilic granuloma complex lesions”; “resistant miliary dermatitis ; ‘resistant 
allergic dermatitis” ; and paronychia.
Diagnosis is based on history, physical examination, cytology, skin biopsy, and response 
to treatment. Cytological examination o f samples from superficial infections reveals neutrophils, 
many o f which are degenerate and show nuclear streaming, with phagocytosed cocci. Samples 
from deep infections show, in addition, numerous lymphocytes, macrophages, plasma cells, and 
eosinophils. As the antibiotic susceptibility o f these staphylococci are stable and predictable, 
culture and susceptibility testing is rarely done.'
Topical therapy can be challenging, but chlorhexidine-containing sprays and shampoos, 
as well as mupirocin ointment are useful.1 Systemic antibiotics are usually indicated. Remember 
to consider mechanisms o f action (“ static” versus “cidal”), user friendliness, food or no food, and 
penetration. Antibiotics must be given until the disease is gone (visually and palpably) plus 
another 7 to 10 days (superficial infections) or 14 to 21 days (deep infections). To this end, 
product labels are rarely adequate. N ever underdose antibiotics when treating skin disease. 
Useful antibiotics include amoxicillin-clavulanic acid (14 mg/kg q l2h), clindamycin (11 mg/kg 
q24h), enrofloxacin (5 mg/kg q24h), and orbifloxacin (2.5 mg/kg q24h).
References
1 . Scott DW, et al. Muller & Kirk's Small Animal Dermatology\ 6th ed. WB Saunders,
Philadelphia, 2001.
2. Thoday KL, et al. Advances in Veterinary Dermatology IV Blackwell Science, Oxford,
2 0 0 2 .
F E L I N E  L E U K E M I A  V I R U S  I N F E C T I O N
The feline leukemia virus (FeLV) is an oncogenic immunosuppressive retrovirus.1 
Although it can induce skin tumors (lymphoma, fibrosarcoma), FeLV most commonly affects the 
skin by its cytosuppressive actions. Clinical signs include chronic or recurrent gingivitis or 
pyoderma (folliculitis, abscess, paronychia), poor wound healing, seborrhea, exfoliative 
dermatitis, generalized pruritus, and cutaneous horns. The viral origin o f the cutaneous horns was 
proved by positive gp70 immunochemical staining and electron microscopy.
A pruritic crusting dermatitis has been described in FeLV-positive cats .1,2 The lesions are 
1.2 scaly, erosive, and crusted, and vary in distribution. All cases have some involvement o f the 
face or head, either around the lips or perioral skin, pinnae, or preauricular skin. Other commonly 
involved sites include the feet or footpads, mucocutaneous junctions o f the anus or prepuce, legs, 
or trunk. At presentation, the cats usually are otherwise healthy. The skin lesions respond poorly 
to treatment with antibiotics, glucocorticoids, interferon, or other agents. With time, the cats 
often show signs o f  internal disease, e.g., anorexia, lethargy, weight loss, but none is usually 
found at necropsy.
All cats are FeLV positive on serology, but skin biopsies are necessary to prove that the 
skin lesions are viral in origin. Histologically, the epidermis is irregularly hyperplastic and 
usually heavily crusted. A characteristic feature is syncytial-type giant cell formation in the 
epidermis and outer root sheath o f the hair follicles to the level o f the isthmus. Keratinocytes 
within and around the giant cells often are apoptotic. Involved skin shows positive gp70 staining 
w hile nonlesional skin from these cats or other FeLV-positive cats with no skin disease is 
negative.
Therapy has been ineffective to date.
References
1 . Scott DW, et al. Muller & Kirk's Small Animal Dermatology, 6th ed. WB Saunders,
Philadelphia, 2001.
2. Scott DW. Dermatoses a cellules geantes associees aux retroviroses chez le chat. Med
Vet Quebec 32:19, 2002.
FFIJN E  IM M UNODEFICIENCY VIRUS INFECTION
Feline immunodeficiency virus (FIV) is another retrovirus that causes a variety o f 
cytosuppressive disorders in the cat.1 The most common clinical sign is chronic or recurrent oral 
disease (gingivitis, periodontal disease, stomatitis). Reported dermatologic signs include chronic 
or recurrent abscesses, chronic bacterial infections o f the skin and ears, an increased frequency o f 
infection with Cryptococcus neoformans, Candida albicans, or Microsporum cams, and 
demodicosis.
A generalized skin disorder has been recognized in FIV-positive cats which might have a 
direct association with the virus .1-2 All cats had a generalized papulocrustous eruption with 
alopecia and scaling, which was most severe in the head and limbs. Pruritus was variable. On 
skin biopsy, a hydropic interface dermatitis was present. Occasional giant keratinocytes were
seen. In addition, a peculiar pallor o f the basal epidermal cells was seen. The cause and 
significance o f this finding remains to be seen. No treatments benefited the cats.
References
1 Scott DW, et al. Muller & Kirk's Small Animal Dermatology, 6th ed. WB Saunders,
Philadelphia, 2001.
2. Scott DW. Dermatoses a cellules geantes associees aux retroviroses chez le chat. Med
Vet Quebec 32:19, 2002.
FELINE HERPESVIRUS INFECTION
Feline rhinotracheitis is an infection with an a-herpesvirus resulting in upper respiratory 
disease. Occasionally, a cat develops oral and cutaneous ulcers.1 The cutaneous ulcers are 
usually superficial and multiple, and can occur anywhere on the body, including the footpads. 
Stress or trauma to the skin might precipitate the development o f the ulcers. Skin biopsies reveal 
epidermal ulceration with subjacent dermal necrosis and a mixed inflammatory infiltrate. 
Intranuclear inclusion bodies may be visualized in the keratinocytes or dermal histiocytes. 
Herpesvirus can be cultured from the skin; more diagnostically, it can be seen in the 
keratinocytes via electron microscopy.
An ulcerative and necrotizing facial dermatitis or stomatitis has been associated with 
herpesvirus 1 infection in cats.1 Affected cats may or may not have active or historical ocular or 
respiratory signs. The disorder is recognized most often in adult cats but kittens can be affected. 
All adult cats had been vaccinated. Typically, crusted skin lesions involve the nasal planum, 
bridge o f the nose, and periocular skin. When the crusts are removed, the exposed skin is 
inflamed and ulcerated. Similar lesions can be found elsewhere on the body. Pruritus is variable.
With intercurrent respiratory signs, the diagnosis is straightforward. Cytology and 
histopathology often contain numerous eosinophils, which has been misinterpreted as indicative 
o f an allergic or ectoparasitic disease.' D iagnosis is via skin biopsy. Serologic test results do not 
confirm active infection nor that the skin disease is due to the virus. In skin biopsies, an 
ulcerative, often necrotic, dermatitis and suppurative folliculitis and furunculosis is seen. There 
is a perivascular-to-interstitial mixed inflammatory cell dermatitis with many eosinophils. In the 
surface and follicular epithelium, multinucleated keratinocytic giant cells can be seen and 
intranuclear (Cowdry type A) inclusion bodies can be seen in the giant cells and other 
keratinocytes. A unique feature o f this disease is necrosis o f epitrichial sweat glands. 
Ultrastructural studies demonstrate intranuclear virions consistent with herpesvirus. Polymerase 
chain reaction (PCR) testing in affected cats was strongly positive for herpesvirus 1. However, 
the use o f PCR as a diagnostic test for feline herpesvirus-associated disease is o f limited value 
because o f the occurrence o f healthy carriers. An immunohistochemical test was reported to be 
accurate.
In adult cats, the disorder can be triggered by stress or corticosteroid usage. Correction of 
these problems with the-use o f antibiotics and other symptomatic treatments may allow for 
spontaneous healing. Other agents suggested include lysine (250 mg o f the formulation without 
propylene glycol orally q24h), a-interferon, and acyclovir. These treatments may or may not be 
beneficial.
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DERM ATOPHYTOSIS
The prevalence o f dermatophytosis in cats varies with environmental circumstances.' 
Thus, it may be rare (0.26% o f all patients) to common (5.6% o f all patients).1 The clinical signs 
attributable to dermatophytosis are also highly variable, reflecting possible differences in: ( 1) 
dermatophyte genera and species, (2) dermatophyte strains, and (3) host im m unoreactivity .1
Because the infection is almost always follicular, the most consistent clinical sign is one 
or many annular areas o f alopecia with variable surface abnormalities (scale, crust, erythema, 
hyperpigmentation, papules, pustules, erosions, collarettes, hair casts). Lesions most commonly 
occur on the face, pinnae, paws, and tail. Pruritus is usually mild to absent. Exam ples o f unusual 
derm atophyte clinical reaction patterns include the following:
1. “M iliary dermatitis”-like.
2. Chin folliculitis/furunculosis.
3. “ Stud tail”-like.
4. Onychomycosis o f one paw.
5. Kerion.
6 . Pseudomycetoma (especially Persians)/ Nodular lesions (mostly subcutaneous) occurring 
commonly over the trunk, with or without “typical” dermatophyte skin lesions. Treatment 
often disappointing.
7. W idespread exfoliative/seborrheic eruption (especially Persians).
8 . Ceruminous otitis externa .3
M. canis infections have great zoonotic potential.1
The differential diagnosis can be lengthy .1 Hi story-taking may be o f limited value unless 
exposure is known to have occurred (veterinary clinic; animal shelter, contagion). Definitive 
diagnosis is obtained via W oods lamp examination (about 50% o f M. canis infections), 
trichography (40% to 70% of the cases in experienced hands; definitive evidence), and fungal 
culture (plucking or brushing; beware mechanical carriage).1 Skin biopsies are useful in all cases, 
especially kerions, pseudomycetomas, and “epidermotrophic” derm atophytosis.1
Dermatophytosis in healthy shorthaired cats often undergoes spontaneous remission 
within 3 m onths.1 Animals with generalized infections require aggressive therapy. Even long­
haired cats undergo spontaneous remission, but it may require P/2 to 4 years!
The goals o f therapy are to: (1) maximize the patient’s ability to respond, (2) reduce 
contagion, and (3) hasten resolution o f the infection. A critical feature o f clinical management is 
the treatm ent o f all in-contact cats and dogs, and, especially in multiple-animal dwellings, 
environmental decontamination.
T o p i c a l  T h e r a p y
Every confirmed case should receive topical therapy .1 Hair is gently clipped/trimmed 
around localized lesions (where practical) or total body in long-haired animals or animals with 
widespread infections. Although clipping (preferably performed by the owners in their own 
already contaminated environment!) may spread the lesions, it is more important to get rid of 
infected hairs. Hair is carefully disposed of. Focal treatments (ointments, creams, lotions) are of 
no proven benefit.
For cats with multifocal or w idespread lesions, and «// cats with M. canis infections, total 
body treatment is indicated .1 Rinses (dips) are preferred as rubbing o f the hair coat (potential 
dispersion o f spores into the coat and environment) is minimized, and the antifungal agent is 
allowed to dry on (residual effect). Lime sulfur 2% and enilconazole 0 .2% - applied once weekly 
- are the most effective.1,4-6 Topical therapy is continued until two consecutive fungal cultures (by 
brush)taken at weekly intervals are negative.
Enilconazole is a much ballyhooed topical treatment in Europe and Canada, but is not 
approved for use in cats in the United States. A poultry premise disinfectant in the United States 
containing 13.8% enilconazole was used to treat dermatophytosis in Persian cats. The product 
was well-tolerated, all cats were culture-negative within 28 days, but all became culture-positive 
again after treatment was stopped. The U.S. poultry product is not the same as the licensed 
European/Canadian product (benzoyl alcohol in U.S. product), and is registered by the EPA (off- 
label use restricted).
S y s t e m i c  T h e r a p y
Cats that have multi-focal lesions, all long-haired animals, and those in multiple-animal 
settings should receive systemic therapy .1 Animals that are not responding to topical therapy 
after a 2- to 4-week course o f treatment should also receive systemic therapy.
Griseofulvin
Griseofulvin (Fulvicin U/F) is the drug o f choice, and the only one labeled for this use in 
the United States. 1,7 A common protocol would be 25 mg/kg PO, q l2h , with a fatty meal. Side 
effects are usually mild, but may be life-threatening in FIV-infected cats. Griseofulvin is highly 
teratogenic and should never be used in the first two-thirds o f pregnancy.
Ketoconazole
Ketoconazole (Nizoral) is effective, but not labeled for use in cats in the United States.' 
The typical protocol is 10 mg/kg PO, q24h, with a meal. Up to 25% of cats experience side 
effects (usually mild at this dosage). Ketoconazole is also teratogenic. Its usage is usually 
reserved for animals that cannot tolerate griseofulvin, or in “resistant” infections (rare!!).
Itraconazole
Itraconazole (Sporanox) is effective, but is not labeled for use in cats in the United 
States.1, The typical protocol is 10 mg/kg PO, q24h, with a m eal.1 Itraconazole is well-tolerated,
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but is teratogenic. It is very expensive and usually reserved for animals that cannot tolerate 
griseofulvin and ketoconazole.
c
Fluconazole
Fluconazole (Diflucan) is effective, but is not labeled for use in cats in the United 
States.1 The typical protocol is 10 mg/kg PO q24h. Fluconazole is well-tolerated. It is very 
expensive and has no advantage over itraconazole.
Terbinafine
Terbinafine (Lamisil) is effective, but not labeled for cats in the United States.1 Studies in 
experimental and natural M. canis infections in cats indicate that the drug is effective (30 to 40 
mg/kg PO q24h) and well-tolerated. 8 Terbinafine is expensive, but fungicidal.
Lufenuron
Lufenuron (Program) has received a lot o f attention - principally anecdotal - since the 
astonishing article by Ben-Ziony and Arzi in 2000 .9 In this article, the authors treated 159 cats 
with dermatophytosis (none with generalized disease!) with lufenuron at 51 to 266 mg/kg PO 
once with a 100% clinical cure (mean 12 to 21 days) and 100% mycological cure (mean 8 to 14 
days!). The same authors later indicated that the lower dosage (-6 0  mg/kg with a meal) had 
failed in some cats, especially those in catteries, and recommended 80 mg/kg for house cats and 
100 mg/kg in catteries.10 In another study involving 100 cats in two catteries, lufenuron (60 
mg/kg PO, twice), topical enilconazole, and environmental enilconazole applications provided ^  
good clinical and mycological improvements which were beginning to deteriorate 2 months post- 
treatm ent.11 Recent studies showed that lufenuron (30 to 140 mg/kg PO, once monthly; or 40 mg 
SQ every 6 months) did not prevent infection nor accelerate healing .12'15
V a c c i n a t i o n
A killed M. canis vaccine (Fel-O-Vax MC-K) was released for the treatment and 
prevention o f dermatophytosis in cats in 1994 . . . with no peer-reviewed, published evidence of 
its efficacy .1 Extensive studies with other killed M. canis vaccines in laboratory cats showed no 
success in preventing or accelerating the healing o f derm atophytosis.1 A recent study with Fel-O- 
Vax M C-K showed that it also did not prevent infection or accelerate healing o f M. canis 
infection in cats .16
E n v i r o n m e n t a l  D e c o n t a m i n a t i o n
In multianimal dwellings (especially catteries) w ith M  canis infections, the environment 
becom es severely contaminated (floors, walls, inanimate objects, transport vehicles, ventilation 
systems), and current decontamination strategies often fail.1 The challenge is daily cleaning and 
disinfection until two consecutive cultures (at weekly intervals) from animals and environment 
are negative. The most effective disinfectants are 0.525% sodium hypochlorite (1:10 bleach), 
stabilized chlorine dioxide (Oxygene), glutaraldehyde and quaternary ammonium chloride (GPC 
8), potassium monoperoxysulfate (Virkon), and enilconazole (Clinafarm EC ).1,7,18 However, 
enilconazole foggers used weekly for 4 weeks did not eliminate environmental contam ination .11
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F E L I N E  D E M O D I C O S I S
Demodicosis is a nonseasonal, variably pruritic infestation caused by 3 different m ites.1 
Demodex cati is long (about 219 pm) and inhabits hair follicles. Details o f its life cycle are not 
known, and it is assumed to be a normal resident o f  feline skin, transmitted to nursing kittens 
within the first few days o f neonatal life. D. gcitoi is shorter (about 108 pm) and inhabits the 
stratum corneum o f the surface epidermis. Details o f its life cycle are unknown, but it is 
contagious to other cats. The third, presently undescribed, demodicid on cats resembles D. gatoi, 
but is longer (about 170 pm) and has other anatomical differences.
D. cati is usually associated with typical folliculitis lesions: annular areas o f peripherally 
enlarging alopecia, scaling, and variable erythema, crusts, and papules .1,2 Lesions may be 
localized or generalized, and are particularly common on the face, head, pinnae, chin, neck, and 
paws. Pruritus is uncommon and, when present, is usually attributable to secondary 
staphylococcal infection. Some cats have a variably pruritic ceruminous externa .1,3 Affected cats 
frequently have concurrent predisposing disorders: hyperadrenocorticism (iatrogenic or 
spontaneous), diabetes mellitus, FeLV and/or FIV infection, and others. D. cati infestation has 
also been reported in the lesions o f squamous cell carcinoma in situ (Bow en’s disease) with or 
without concurrent FIV infection .1,4
D. gatoi is usually associated with widespread - especially trunk and limbs - traumatic 
hair loss, scaling, and pruritus. M ultiple cats in the same household may be affected .1,5 Most 
affected cats are otherwise healthy.
The differential diagnosis for D. cati typically includes other causes o f folliculitis: 
dermatophytosis, staphylococcal infection, and pemphigus foliaceus/erythematosus. Typical 
ruleouts for I), gatoi include atopy, food hypersensitivity, and adverse drug reaction. Skin 
scrapings are diagnostic for demodicosis caused by D. cati. D. gatoi can be missed if  you do not 
use the 10X objective and close down the diaphragm. In some cases o f  D. gatoi-mduced disease, 
the diagnosis is confirmed by finding mites on normal in-contact cats, or by response to therapy.
Therapeutic options include topical 2% lime sulfur (D. gatoi) or off-label topical 125-250 
ppm amitraz (D. gatoi and I), cati). Demodectic otitis externa can be treated with various ear 
mite otic preparations as well as off-label applications o f amitraz in mineral oil or propylene 
glycol (1:9). In case o f D. gatoi infestations, all in-contact cats need to be treated. Weekly 
treatment with selamectin was not curative for D. gatoi infestations.7 Milbemycin (2 mg/kg q24h 
PO) may be effective in D. cati infections. 6
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ATOPIC DERM ATITIS
Feline atopic dermatitis ([FAD]; atopy, allergic inhalant dermatitis) owes its birth and 
current level o f interest and recognition to Dr. Lloyd Reedy, whose landmark article on 
intradermal (“skin”) testing and allergen-specific immunotherapy (“hyposensitization”) in cats 
was published in 1982. Atopic dermatitis is defined as a genetically-predisposed inflammatory 
and pruritic allergic skin disease with characteristic clinical features, that is most commonly 
associated with IgE antibodies to environmental allergens. 2,3
A complex pathogenesis o f immune dysregulation in interplay with genetic, 
environmental, anatomical, microbial, climactic, and physiological factors is envisioned. 4-5 A 
summary o f current thought as to the possible pathogenesis o f atopic dermatitis in humans, dogs, 
and cats is presented in Table I . 3"5
No detailed study has been reported on the hereditary aspects o f FAD. However, in one 
study ,6 5 o f 16 (31.9%) atopic cats had close relatives with atopic-like skin disorders. In another 
study ,7 FAD was diagnosed in related Abyssinian cats. M ost recently ,8 FAD was diagnosed in 3 
littermates, at the same age, living in the same household. There are presently no apparent age, 
breed, or sex predilections, although over 75% o f the atopic cats in 2 studies6,8 developed their 
clinical signs between 6 months and 2 years o f age.
The prevalence o f FAD is unknown, but it is generally thought to be the second most 
common allergic skin disease in cats (after flea allergy ).3 FAD accounted for 12.1% and 16% of 
the cases o f “miliary dermatitis” in 2 studies,6,9 17%, 35%, and 73% o f all allergic cats in 3 
studies,10'12 and 5.6% o f all feline dermatoses seen over a one-year period at a university clinic . 13
The clinical signs o f FAD may be initially seasonal (warm weather in association with 
pollens and outdoor molds; cold weather in association with house dust, danders, and indoor 
molds) or nonseasonal, or progress from seasonal to nonseasonal.3,10,14,15 The most common 
dermatologic findings are presented in Table 2 . 3>10-14-15 These cutaneous reaction patterns may be 
seen in various combinations in any given cat.
Reactions to house dust mites (Dermatophagoides farinae and D. pteronyssitms) and 
storage mites (Acarus siro, Blomia tropical is, G/ycyphagus domesticus, Lepidoglyphus 
destructor, Tyrophagus putrescentiae) are the most common in FAD, followed by pollens, 
molds, and danders.1,3,10-12,14'16 House dust and storage mites are related to Otodectes, Sarcoptes, 
Notoedres, Cheyletie/la, and other mites. Not surprisingly, false-positive reactions (intradermal 
and serological) can occur in cats with these parasites.3 W hereas most atopic humans react to low 
molecular weight house dust mite allergens (D erf 1 and II, Derp I and II), most cats react to 
higher molecular weight allergens.3,16
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The diagnosis o f FAD is first and foremost clinical, and is based on com patible history, 
physical findings, elimination o f other causes, and response to therapy. 3 “ Allergy testing” 
(NOT!) is performed - not to establish a diagnosis - but to determine allergens to be considered 
for avoidance and immunotherapy protocols.3
Allergen-specific immunotherapy based on carefully selected and prepared patients, and 
carefully interpreted intradermal test results, “benefit” (total control, or marked reduction in 
required medicines) 50% to 73% of atopic cats.1,3,6,8,10,11,17-20 Intradermal testing remains the 
“cadillac” , as false-positive reactions are less common, and positive reactions more frequently 
make sense with the cat's  history .3 However, this technique is more labor-intensive, and requires 
sedation, clipping, and expertise. Short-acting glucocorticoids (oral, topical) must be withheld 
for at least 3 weeks, repositol glucocorticoids pending the product (at least 6 to 8 weeks), 
antihistamines and omega-6/3 fatty acids (including Eukanuba®  diets) for at least 10 days . 3
Although in vitro serological allergen-specific IgE tests have been available since 1985, 
and new companies and techniques continue to come on the scene, rarely is scientific 
information available on the methodologies, specificities, and utility o f the tests .3 Despite 
“refinements” and “improvements” in serological tests, false-positives, false-negatives, and lack 
o f correlation with intradermal test results persist.3,21 M anufacturers tout the benefits o f their 
methodologies - liquid-phase immunoenzymatic assay (VARL), FcsRIa-based ELISA 
(HESKA), enzyme-linked immunosorbent assay (ELISA), radioallergosorbent test (RAST) - 
with little or no peer-reviewed science to back them .3 Serological tests are also influenced by 
glucocorticoids and season. Attempts to create in-office “ screening tests” have always been a 
dismal failure and should be avoided like the plague.3
The keys to maximizing the success o f an£ “allergy testing” are: (1) choosing a good test, 
(2) patient selection (rule-outs, drug withdrawal), (3) observing seasonal influences, and (4) 
matching test results with patient. 3 I f  money and availability were no problem, it is probable that 
the best results o f  allergen-specific immunotherapy would be achieved by performing both skin 
and serological testing on every patient. 3
T a b le  1. Pa thogenes is  of  Atopic  Derm a t i t i s3 5
Genetic predisposition 
Complex
This not sufficient alone 
Environment
“Hygiene hypothesis”
Epidermal barrier dysfunction
ILipids/ceramides in stratum comeum 
Percutaneous allergy absorption 
Lesional and normal skin 
Th2-biased response
Antigen-presenting cells armed/1 expression o f IgE 
IL-4, IL-5, EL-13 
Eosinophils 
Ig switch 
“Extrinsic” versus “intrinsic” forms 
“Good” and “bad” IgE 
Late-phase response 
Mast cell/basophil releasibility 
Overactive phosphodiesterase isoforms 
Stem cell factor
1 in lesional/normal skin 
Keratinocytes
1 defensins 
Secondary factors
* Staphylococci (adhesion; superantigen; upregulate IgE synthesis; infection) 
*Malassezici (adhesion; hypersensitivity; infection)
* Autoimmunity (epidermal/dermal components)
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T a b l e  2. Clinical  F e a tu r e s  o f  FA D
Age o f onset: 6 months to 2 years
Familial history
Seasonality
Dermatoses
Self-induced hypotrichosis (“fur-mowing”) 
Papulocrustous dermatitis (“miliary dermatitis” ) 
Eosinophilic granuloma complex 
Itch that rashes (face, pinnae, neck, paws) 
Conjunctivitis 
Rhinitis
Peripheral lymphadenopathy
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FOOD HYPERSENSITIVITY
Food hypersensitivity (food allergy, food intolerance, adverse food reaction) is common 
in cats, accounting for 11% of all cats with “miliary dermatitis” ,1 17% to 23% of all cats with 
allergic skin disease,-3 1% o f all patients seen in general practice ,4 7 .6% o f the cases in private 
dermatology referral practice, 5.8% o f the dermatology cases seen in university practice,6 or 
10% ot all allergic skin diseases. The pathogenesis o f  adverse reactions to foods in cats is poorly 
understood, with immediate and “ delayed’ reactions recognized. The most commonly 
incriminated food items are fish, beef, and dairy products. However, a wide variety of 
substances are capable o f being antigenic (see Table l ).7
Food hypersensitivity has no sex predilection, and occurs in cats 3 months to 14 years o f 
age (up to 50% o f the cases occur in animals < 1 year old). M ost authors report no breed 
predilections, while others incriminate Siamese cats.* M ost animals have nonseasonal pruritus, 
though episodic or seasonal disease can be seen, reflecting antigenic exposure or concurrent 
atopy. In cats, reaction patterns include pruritus o f the face/neck/ears/paws/tail, “miliary 
dermatitis , eosinophilic granuloma complex, and self-induced hypotrichosis (“ fur mowing” ).5-9 
Cats may develop exfoliative dermatoses, pruritic or non, with histologic lymphocytic mural 
folliculitis. 10 Gastrointestinal disturbances are seen in about 15% o f the cases.7 Malaise, 
dullness, and lethargy may be seen .711
At present, the definitive diagnosis o f food hypersensitivity can only be achieved on the 
basis o f elimination diets and provocative exposure testing. Novel protein (“hypoallergenic”) 
diets must be individualized for each patient on the basis o f careful dietary history. The 
objectives are to feed the patient substances not commonly encountered and to avoid additives 
(colorings, flavorings, preservatives). 1- Home-prepared diets are best. Such diets are 
nutritionally inadequate for maintenance and should not be used in growing animals. 13 D on’t 
forget to eliminate “chewable,” “flavored,’ “gelatin encapsulated,” etc. substances (e.g., vitamin- 
mineral-fatty acid supplements, heartworm preventive). Owners and veterinarians must become 
vigilant ingredient label readers and pick out those “hidden” allergens: animal digest, animal by­
products, poultry by-products, natural vitamin A (fish oil), proteinate, mixed vegetable oils, 
animal fats, bone meal, and modified food starch. Animals with rapidly relapsing bacterial and 
yeast infections may need to be kept on antimicrobials during the dietary trial.
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Very little information is available on the “sea” o f novel protein and hypoallergenic diets 
that veterinarians are besieged with. When known food hypersensitive cats were fed commercial 
novel protein diets, 20% to 65% of the animals became pruritic and derm atitic.14,15 Additionally, 
when food hypersensitive cats were fed “all” available commercial novel protein diets, 7.7% to 
31% became pruritic .6,8,16
The necessary duration of a novel protein diet is controversial, with some authors 
indicating that 10 to 13 weeks are necessary .6,8,9 M yself and others" would expect to see some 
signs o f response within 4 to 6 weeks, though maximum improvement may take longer. The 
diagnosis is confirmed when (1) there is at least a 50% reduction in pruritus, (2) feeding the 
previous diet causes a relapse (within 14 days), and (3) refeeding a novel protein diet “rescues” 
the anim al.7 Animals rarely become allergic to something in their novel diet in the future. About 
8% to 30% of food hypersensitive cats are also atopic .3,6,8,16 This can obviously complicate the 
diagnostic workup and therapy.
Skin and serologic “allergy tests” are worthless for the diagnosis o f food hypersensitivity
in cats .7,11,18
Therapy is most effective when based on novel protein diets. Unfortunately, from 7.7% to 
31% o f food hypersensitive cats could eat no available commercial diet without relapsing .6,8,16 
Steroidal and nonsteroidal agents are useful, but about 50% o f food hypersensitive cats are 
poorly responsive to glucocorticoids.
Table 1. Reported Food Allergens in Cats
Barley Eggs
B eef Fish (variety)
Benzoic acid Food additives
Chicken Food preservatives
Clam juice Horse meat
Cod liver oil Lamb
Commercial diets Lactose
Corn Pork
C ow ’s milk Rabbit
Dairy products W hole meat
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Feline pancreatitis is a very difficult disease to definitively diagnose antemortem and 
treatment remains symptomatic and supportive. This partly due to the lack of specific clinical 
signs in cats, as well as the lack of a specific and sensitive test for diagnosis of the disease -  
especially in cats with chronic pancreatitis. This talk will review the salient features of both 
acute and chronic pancreatitis in cats and discuss the treatment of cats with pancreatitis -  a 
problem intensified by the complications that develop in anorectic cats.
Diagnosis
The clinical signs of feline pancreatitis are quite different from those in dogs. Acute 
pancreatitis is frequently encountered in obese dogs fed a high fat diet, while cats are more likely 
to be underweight, and high fat diets do not appear to be an important predisposing factor. Cats 
of all ages, sexes and breeds are affected, although Siamese cats are reported to have pancreatitis 
more frequently. Finally the clinical signs of pancreatitis in cats are more vague, with the most 
common signs being lethargy (reported in 100% of cats in one study), anorexia, dehydration and 
abnormal body temperature (either fever or hypothermia can be observed). Vomiting and 
anterior abdominal pain, which are common clinical signs in dogs with acute pancreatitis, occur 
in only 35% and 25% of cats, respectively. Cats with severe necrotizing pancreatitis may be 
icteric or in shock. Other conditions that may occur concurrently with pancreatitis in cats 
include hepatic lipidosis, cholangiohepatitis, inflammatory bowel disease, interstitial nephritis, 
diabetes mellitus or vitamin K responsive coagulopathy. Thus, the clinical signs may be quite 
variable, and this must be taken into consideration with each patient. In addition, with increases 
in liver enzymes and bilirubin, the signs and abnormalities can easily be attributed to liver 
dysfunction, which further delays the diagnosis.
Routine evaluation of cats with suspected pancreatitis may include hematology, a serum 
biochemistry profile, urinalysis, abdominal radiography and/or ultrasound, and serum assays of 
pancreatic function (e.g. feline trypsin like immunoreactivity -fTLI, or feline pancreatic lipase 
immunoreactivity -  fPLI). Hematologic findings in cats with pancreatitis are nonspecific, but 
may include a nonregenerative anemia, leukocytosis or leukopenia (less common). In a recent 
study, cats with pancreatitis consistently had an elevated WBC (20,300 cell/uL) and mild 
decreases in platelets (mean = 180,000 platelets/uL). Reported changes in the serum chemistry 
profile include elevated serum alanine aminotransferase (ALT), elevated serum alkaline 
phosphatase (ALP), hyperbilirubinemia, hyper- or hypocholesterolemia, hyperglycemia, 
azotemia, and hypokalemia. In a recent study, the most common abnormalities in cats with 
severe pancreatitis were hyperglycemia (180 mg/dL), hyperbilirubinemia (2.5 mg/dL), 
hypocholesterolemia (130 mg/dL), and hypoalbuminemia (1.8 g/dL). Liver enzyme elevations 
were more common in cats with mild pancreatitis (determined by surgical biopsy), and GGT 
ALP, and ALT were all moderately elevated in these cats. Hypocalcemia is less commonly 
observed, but when present may be a poor prognostic sign seen in cats with severe pancreatitis or 
multiple organ dysfunction. Serum lipase may be increased early in acute pancreatitis, but in a 
recent study amylase and lipase were found to be of little diagnostic value in distinguishing
normal cats from those with pancreatitis. There are no changes in the urinalysis consistently 
observed or specific for pancreatitis in cats.
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The fTLI was developed years ago as the definitive test for diagnosis of exocrine 
pancreatic insufficiency, and the data and follow up have confirmed its utility for this condition.
In recent years, others have evaluated the fTLI as a diagnostic test for acute pancreatitis -  
working on the premise than an elevation in serum concentrations were consistent with 
pancreatic leakage or inflammation. While an increase in fTLI can be found in cats with acute 
pancreatitis, a normal fTLI does not rule out pancreatitis. This is because the leakage of 
enzymes tends to decrease or is controlled by the body’s peptidases (macroglobulin, etc) 
withinl2-24 hours following an acute insult. Further, in chronic or low grade pancreatitis, the 
leakage is not great enough to be detected by this assay. Thus, while an increase in fTLI is 
specific for pancreatic enzyme leakage, it is not sensitive enough to be a definitive test for 
pancreatitis. More recently, an ELISA for pancreatic specific lipase (feline pancreatic lipase 
immunoreactivity -fPLI) was developed by the GI lab at Texas A&M University. The assay is 
species specific, has been used to detect elevations in pancreatic lipase in clinical cases, and 
appeared to be more specific and sensitive for diagnosis of pancreatitis in cats than fTLI. 
However, the assay had a relatively low sensitivity (33%) and specificity (<80%) when a cut off 
value of 100 ug/L was used for diagnosis. To improve upon this assay, a radioimmunoassay 
(RIA) was developed and validated in 30 healthy cats. In a recent paper, the sensitivity and 
specificity of this assay was tested in cats with mild pancreatitis and in cats with moderate to 
severe pancreatitis. The sensitivity in mild pancreatitis was found to be 80% while the 
specificity in healthy cats 75%. However, in severe pancreatitis (determined by pancreatic 
biopsy) the sensitivity and specificity were both 100%. These findings underscore the utility of 
this test in cats with acute pancreatitis, however, there still is a problem with detection of low ^
grade or chronic pancreatic inflammation in cats with this assay. In cats with chronic 
pancreatitis it will still be necessary to evaluate the combined historical, physical exam, lab data 
and imaging information along with the fPLI when making a diagnosis.
Imaging studies are frequently used to help identify cats with acute pancreatitis, however, 
the changes are not consistent and can be particularly subject to interpretation and operator 
expertise. The most common radiographic abnormalities include a generalized or focal (upper 
right quadrant) loss of peritoneal detail (suggesting peritonitis or peritoneal effusion), presence 
of a mass in the area of the pancreas, hepatomegaly, dilated intestinal loops, or a fluid-filled 
duodenum. However, these findings are not specific for pancreatitis, and the sensitivity of 
radiography for diagnosing pancreatitis is low in cats. Ultrasonography may reveal a hypoechoic 
pancreas, hyperechoic mesentery, a mass effect, a dilated common bile duct or it may be normal.
In previous studies, the sensitivity of ultrasound for diagnosis of pancreatitis was reported to be 
24%. In a recent study, mild pancreatitis was still shown to be difficult to diagnose via 
abdominal ultrasound. However, in that same study, ultrasound had 80% sensitivity and 88% 
specificity in cats with moderate to severe pancreatitis. In humans, the “gold standard” for a 
noninvasive diagnosis of pancreatitis, but in this study, only 2 of the 10 cats showed evidence 
consistent with pancreatitis and there was large variability in the ability of this imaging technique 
to assess pancreatic size. As such, the cost, availability, the difficulties in imaging the normal 
feline pancreas using CT, make this method less attractive and unrealistic for use in the diagnosis 
of feline pancreatitis. The most reliable method for making an accurate diagnosis of pancreatic 
disease remains direct visualization and histopathology. However, this can be expensive, ,^j 
increase the risk of complications (anesthesia/surgery), and in cases with focal lesions, the 
lesions may be missed on visual or histopathologic inspection.
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Treatment of Pancreatitis
Acute pancreatitis in cats can be a significant therapeutic challenge. As with the 
treatment of dogs, the therapy is supportive and aimed at restoring circulating blood volume 
while allowing the pancreas to “rest”. If an inciting cause can be identified, it should be 
corrected; however, greater than 90% of cases are idiopathic. The mainstay of treatment is 
aggressive fluid therapy, and if the cat is vomiting, withholding food and water for 2-3 days. 
Colloid support can be obtained with hydroxyethyl starch (Hetastarch) or plasma if it is 
available. Plasma can be especially beneficial, as it provides additional alpha macroglobulins 
which are important scavengers of pancreatic enzymes. If the cat is unable to tolerate water or 
food after the 2-3 day period, alternative routes of nutritional support must be considered to 
prevent development of hepatic lipidosis or protein/calorie malnutrition and immunosuppression. 
The preferred method of nutritional support for cats with severe pancreatitis is via a jejunostomy 
(J) tube, but this requires an invasive procedure and may not be possible in all cats. Partial or 
total parenteral nutrition are viable alternatives. If the cat is not vomiting, placement of an 
esophagostomy (E) or percutaneous endoscopic gastrostomy (PEG) tube are reasonable 
alternatives -  especially in cats with known or suspected hepatic lipidosis as a concurrent 
problem. The key point is this: you can t starve cats with pancreatitis -  if they are not vomiting, 
use low fat enteral nutrition and “feed through the pancreatitis. In cats with chronic, low grade 
pancreatitis this is even a more important aspect of long term management.
Other aspects of therapy that must be considered in cats with pancreatitis are pain 
management (whether or not they show overt pain this is important). Careful palpation in most 
cats will reveal cranial quadrant pain in cats with significant pancreatic inflammation. Pain relief 
can be achieved with buprenorphine (0.005-0.01 mg/kg IV, or IM q 4-8 hr), meperidine (1-2 
mg/kg IM q2-4 hr), or butorphanol (0.2-0.4 mg/kg IM q2-4 hr). In addition, low dose CRI 
ketamine or lidocaine infusions are effective in reducing somatic pain, and lidocaine at these low 
doses has prokinetic activity. Morphine should be avoided as it can cause pancreatic duct 
spasm.
Other aspects of supportive therapy to consider are antibiotic therapy, control of vomiting, 
use ot pancreatic enzymes, anti-coagulants (for cats in DIC), and finally, anti-inflammatory 
(steroid) therapy. Antibiotic therapy is generally indicated in all cats with severe pancreatitis, 
anorexia for long periods, or in cats with systemic inflammatory response syndrome (SIRS) as 
the risk of bacterial translocation and secondary sepsis are considerable. In general, broad 
spectrum antibiotics that cover intestinal aerobes and anaerobes should be chosen. Cefotaxime at 
a dose of 50 mg/kg administered intramuscularly every eight hours prevents bacterial 
colonization of the pancreas.
Anti-emetic agents -  Nausea and vomiting may be severe in affected animals. The 012 
adrenergic antagonists and 5 -HT3 antagonists appear to be the most effective anti-emetic 
agents in the cat. Cats may be treated with chlorpromazine (012 adrenergic antagonist) at a 
dose of 0.2-0.4 mg/kg administered subcutaneously or intramuscularly every 8 hours, or with 
any of the 5 -HT3 antagonists (ondansetron 0.1-1.0 mg/kg, granisetron 0.1-0.5 mg/kg, or 
dolasetron 0.5-1.0 mg/kg, orally or intravenously every 12-24 hours). Dopaminergic 
antagonists, e.g., metoclopramide, are less effective anti-emetic agents in the cat, and because 
they antagonize dopamine, may potentially reduce pancreatic blood flow (this effect has not 
been proven in cats with pancreatitis).
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• Calcium gluconate supplementation -  Hypocalcemia is a frequent complication of feline 
acute necrotizing pancreatitis. Calcium gluconate should be given at doses of 50-150 mg/kg 
intravenously over 12-24 hours, along with measurement of serum total or ionized calcium 
concentrations to allow adjustments in therapy.
• Hi and H 2 histamine antagonists -  Histamine and bradykinin-induced increases in 
microvascular permeability are associated with the development of hemorrhagic necrosis in 
experimental feline pancreatitis. Treatment with Hi (mepyramine, 10 mg/kg) and H 2 
(cimetidine, 5.0 mg/kg) histamine receptor antagonists protects against the development of 
hemorrhagic pancreatitis in these feline models. Efficacy has not been established in clinical 
pancreatitis, but the use of these drugs in suspected or proven clinical cases seems 
appropriate. Diphenhydramine (2-4 mg/kg) or dimenhydrinate (4-8 mg/kg) are examples of 
clinically used Hi histamine receptor antagonists. Cimetidine (5.0 mg/kg), ranitidine (1.0-2.0 
mg/kg), famotidine (0.5-1.0 mg/kg), and nizatidine (2.5-5.0 mg/kg) are examples of H 2 
histamine receptor antagonists.
• Low dose dopamine infusion -  Low dose dopamine infusion (5 pg/kg/min) improves 
pancreatic blood flow and reduces microvascular permeability in feline experimental 
pancreatitis. Low dose dopamine infusion is effective treatment in experimental pancreatitis 
even when it is given up to 12 hours after induction of the disease. Part of the appeal of 
dopamine as a potential treatment for feline pancreatitis lies in the diversity of its actions 
(cardiac, renal, and systemic pressure).
• If the cat is hyperglycemic (suggesting glucose intolerance or diabetes mellitus), regular 
insulin should be administered (lU/kg/day via continuous IV infusion or 0.2 U/kg IM q4-6h).
• Steroid therapy was once controversial, and is not recommended in cats with acute, 
necrotizing pancreatitis or pancreatic abscessation. But, there appears to be increasing 
evidence of an association with pancreatitis and IBD in cats, and in these cases, steroid 
therapy is clearly indicated.
• Ductal decompression -  Surgical decompression of the pancreaticobiliary duct should be 
considered in cases of acute ductal obstruction, e.g., calculus, neoplasia, and fluke infection. 
Ductal decompression has been shown to restore pancreatic blood flow, tissue pH, and acinar 
cell function.
• Ductal decompression may also be useful in acute cases that have progressed to the more 
chronic form of the disease.
The diet chosen should be highly digestible and low fat to reduce stimulation of 
pancreatic secretions. In some cats, a homemade, low fat diet (e.g. chicken/turkey and rice in 2:1 
proportions) may be beneficial, as there are no commercially available feline diets that are both 
very highly digestible and very low in fat. Ultimately, the goal is to find an appropriate diet for 
the cat that is both commercially available and acceptable to the cat. An important point about 
feeding cats during this period is to avoid force feeding -  not only because it is very difficult to 
achieve the appropriate level of caloric intake by this method, but also because it can induce food 
aversion.
Partial (Peripheral) Parenteral N utrition (PPN)
Parenteral nutrition is nutrition delivered by an intravenous route. While enteral nutrition is 
always preferred, parenteral nutrition can be life saving in cats that cannot tolerate enteral 
feeding or are unable to meet their energy needs by enteral nutrition alone. Total parenteral 
nutrition, which allows provision o f all the cat’s daily nutritional needs intravenously, are 
hyperosmolar solutions and must be delivered through a central venous catheter. The logistics of 
stocking and compounding the required solutions, placement of central venous catheters and 
their care, and the provision of intensive patient monitoring around the clock have limited the use 
of total parenteral nutrition (TPN) to large practices and teaching hospitals. In recent years, 
major innovations in catheters (less thrombogenic and less prone to kinking) have made use of 
peripheral nutrition more practical and possible. While there are still drawbacks and limitations 
to PPN, the process has been greatly simplified.
In general. PPN is used in cats requiring nutritional support for less than one week, as it is 
intended to be gap nutrition -  in other words, to fill the gap until better support (or complete 
support) can be provided.
Key Issues
• PPN is used to provide up to 50% of the of the patient’s energy needs for 24 hr. Thus, unlike 
TPN, it cannot be the only source of nutritional support for a patient for more than a few 
days.
• PPN does not require a central venous line — only a dedicated peripheral catheter is required.
• Because the PPN catheter must not be used for other purposes to reduce the risk of sepsis, a 
second catheter must be placed for fluids, blood draws, etc.
• Silicone elastomer or polyurethane catheters appear to be the least thrombogenic than 
commonly used Teflon catheters
• Placement of the catheter as a sterile procedure is a must — PPN solutions are ideal for 
growth o f bacteria.
• Minimize changes/opening connections — change drip sets every other day — don’t reuse 
them with new PPN solution.
• The basic solution is a protein source (8.5% amino acid solution), a CHO source (5 % 
dextrose), and a fat source (20% lipid emulsion), with added vitamins, minerals and 
electrolytes as needed.
• The key difference for PPN versus TPN is the osmolarity of the solution. TPN is often > 
1200 mOsm/L, while the goal is to keep PPN solutions < 800 mOsm/L.
• 5% Amino acid solutions < 500 mOsm/L and 20% lipid solutions are 340 mOsm/L -  it is the 
CHO solutions used that can increase osmolarity, thus 5-10% solutions are used to reduce 
this problem.
• PPN solutions must be mixed under aseptic conditions and in a specific order -  it is best to 
have them formulated by a pharmacist if possible — and they must be used within 24-36 hours 
once administration is started.
Order: AA + dextrose, then electrolyte and vitamin/mineral solutions, finally add lipids last 
-  care should be taken to avoid precipitation (if it occurs, the solution must be discarded).
• Delivery of PPN solutions must be continuously via an infusion pump. Both slow initiation 
and slow cessation of PPN administration is essential to prevent metabolic crises 
(hypo/hyperglycemia, hypertriglyceridemia, etc).
• Decide the amount of calories to be administered for the patient (using the same calculations 
as for enteral nutrition).
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Nutrient Requirements:
Cats (< 10 kg)
IER x 0.50 (50% of nutrients/day) x 0.25 (% kcal from dextrose) = kcal/day from dextrose 
IER x 0.50 x 0.25 = kcal/day from amino acids 
IER x 0.50 x 0.50 = kcal/day from lipid
Volume Requirements for Solutions
1. 5% Dextrose = 0.17 kcal/ml
kcal/day 0.17 kcal/ml = ml/day dextrose
2. 8.5% amino acid solution w/ electrolytes = 0.34 kcal/ml 
kcal/day 0.34 kcal/ml = ml/day amino acids
3. 20% lipid solution = 2 kcal/ml 
kcal/day -s- 2 kcal/ml = ml/day lipid
B complex solution = 2-4 ml/L
Add each component to give the total volume (ml) of PPN solution 
Total volume + 24 hr = ml/hr (approximates a maintenance rate of fluid)
• The most common complications are with catheter occlusion, premature removal, line
disconnection or thrombophlebitis. These problems can be minimized with proper catheter 
placed and patient monitoring.
• Metabolic complications with TPN are much greater than with PPN, but still must be 
considered. The most common complication of PPN is hyperglycemia. Hyperammonemia
and hypertriglyceridemia are much less common with PPN than TPN and if they occur,
require reformulation of the solution.
• Volume overload can occur in patients with congestive heart failure or renal failure, or in 
very small dogs or cats -  intravenous fluid rates must be adjusted to account for the volume.
• The most serious complications are venous thrombosis and septicemia secondary to catheter 
infection or solution contamination. Any change in body temperature should be immediately 
assessed and addressed.
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Pruritus and the various aberrations o f skin and hair coat that it provokes are, by far, the most 
common reasons for which cats are presented to veterinarians for dermatologic diagnosis.' Although 
many different dermatoses can be pruritic, and the differential diagnosis of pruritus is complicated, 
allergic (hypersensitive) skin diseases are certainly the most common causes of pruritus in cats.
Pruritus is defined as a sensation that elicits the desire to scratch.1 The pathophysiology of 
pruritus is complicated and poorly understood for most diseases in most species. The literature is 
plethoric with information on various mediators and modulators of pruritus. However, the relative 
importance of these mediators and modulators in any given species, disease, or individual is rarely 
known.
In our practice, the most common reason for having difficulty in managing the allergic patient 
is failure to frequently reconsider the "threshold phenomenon" and the "summation of effects". Any 
"allergic" patient that is difficult to control or suddenly "comes out of control", needs to be reassessed 
for other problems (secondary bacterial pyoderma, secondary M alassezia  dermatitis, flea infestation, 
dry skin, contact dermatitis, etc.) before its allergy medicine is adjusted.
SYSTEMIC THERAPY
Glucocorticoids are, without a doubt, the most used and abused compounds in veterinary 
dermatology.1 They are also the most consistently effective drugs in the management of allergic 
pruritus in cats, and can be used effectively and safely in many patients (Table 1). All glucocorticoids 
are not created equal. Thus, if a patient does not do well with one glucocorticoid, a different one may 
be more acceptable. Some cats do not appear to be able to convert prednisone to prednisolone; hence 
using the latter is more effective. The concept of "tolerable itchiness" must be stressed to the owners. 
Situations do arise wherein the use of glucocorticoids is undesirable or contraindicated. Examples 
would include: (1) objectionable acute or chronic side effects, (2) certain concomitant diseases (e.g., 
diabetes mellitus, pancreatitis, renal failure), (3) concurrent infections (bacterial, fungal, viral), (4) 
concurrent immunodeficiency states (e.g., FIV, FeLV), and (5) owners who are "cortisone"- or 
"steroid"-conscious. For these reasons, clinical and research interest in nonsteroidal antipruritic 
agents has "exploded" in the last several years. Although nonsteroidal antipruritic agents are often 
useful in the management of allergic cats, they do not have an immediate antipruritic and anti­
inflammatory effects. Hence, it is often necessary to give glucocorticoids along with the nonsteroidal 
agents for the first 3 to 7 days.
ANTIHISTAMINES
All "traditional" Hi-blockers have antihistaminic, anticholinergic, sedative, and local 
anesthetic effects.1'6 They must be used with caution, if  at all, in the presence of liver disease, 
glaucoma, urinary retention, gastrointestinal atony, seizures, pregnancy, and nursing queens. 
Responses are notoriously individualized and unpredictable. Thus, one often has to try several before 
the one that is "right" for the patient is found (Table 2). Each antihistamine should be tried for at least
two weeks. Concurrent antihistamine administration often allows reduced glucocorticoid dose^ 
Antihistamines are often synergistic with omega-3/-6 fatty acids.
HFTFROCYCLIC ("TRICYCLIC") ANTIDEPRESSANTS
In addition to poorly-defined behavior-modifying properties, these agents are very potent H-blockers 
(Table 3).1,2 In addition to classic antihistamine side effects, these agents can also cause cardiac 
arrhythmias, lower seizure thresholds, and potentiate side effects of monoamine oxidase inhibitors 
(amitraz). Cardiac side effects have not been produced in cats with normal cardiac function. Like 
antihistamines, heterocyclic antidepressants often act synergistically with glucocorticoids and omega- 
3/-6 fatty acids.
OMFr.A-3/QMEGA-6 FATTY ACIDS
Fatty acid supplements containing omega-3/omega-6 fatty acids are potent modulators of 
prostaglandin and leukotriene synthesis.1 They rarely cause side effects. Numerous clinical trials have 
shown that these agents are useful in many allergic cats, and may also act synergistically with 
glucocorticoids and antihistamines.5,7'9 The literature is very confusing as concerns the “correct’ 
dosage, ratio, and type of omega fatty acid to be used. Most o f this is directly attributable to a failure 
to consider the patient’s base diet.
A commercial lamb and rice dog food (Eukanuba Natural® Lamb and Rice) with an omega- 
6:omega-3 fatty acid ratio of 5.5:1 was fed in a single-blinded, self-controlled clinical trial to J *  
atopic dogs. The pruritus in 8 of these dogs (44.4%) was controlled within 7 to 21 days, returnee 
within 3 to 14 days after the diet was withdrawn, and was again controlled when the diet was 
reinstated. Some of these dogs had failed to respond to recommended doses o f Derm Caps.® The dog 
food supplied about 6 times the y-linolenic acid (about 6 mg/kg) and eicosapentaenoic acid (about 9 
mg/kg) as what is found in the commercial supplement. When the commercial dog foods being fed to 
these dogs were analyzed, tremendous variation in quantity, ratio, and types of omega-6/-3 fatty acids 
was found. In addition, it appears that atopic dogs have a partial deficiency in A6- desaturase and, in 
some cases, A5-desaturase activities. Hence, simply supplying these dogs with linoleic acid (omega- 
6) and a-linolenic acid (omega-3) may not be adequate. If the clinician really wants to know whether 
or not a dog will benefit from omega-6/-3 fatty acids, a commercial diet with controlled amounts and 
ratios (Eukanuba® Lamb and Rice, Eukanuba® F/P, Eukanuba® K/O) is preferable. Otherwise, 
selecting a commercial supplement without knowledge of the dog’s base diet is fraught with 
misinterpretation and frustration. 1 assume that the same applies to cats until proven 
otherwise."1
TYrLOSPORINE
Cyclosporine is a potent inhibitor of T lymphocyte-dependent immune responses.1 Its various 
effects include decreased 1L-2, IL-3, IL-4, IL-5, TNF-a, and IFN-a production; inhibition of antigen 
presentation, eosinophil-and mast cell production, histamine release from mast cells, neutrophil 
adherence, and growth and differentiation of B lymphocytes. The microemulsified forms (Atopica,® 
Novartis: capsules; Neoral,® Novartis: capsules and emulsion; generic) are preferred (betti^L  
absorption) over the original forms (Sandimmune,® Novartis). Drugs that inhibit cytochrome P-45v- 
enzymes (macrolides, azoles, tetracyclines, large doses of glucocorticoids) increase cyclosporine
blood levels. Recommended initial dosage is 5 mg/kg q24h PO for cats. Side effects are common 
(especially gastrointestinal) but usually mild. Many cats can eventually be controlled with 5 mg/kg 
q48h or even twice weekly.11-13 Atopica® is not approved for use in dogs less than 6 months of age, n- 
13 dogs weighing less than 4 pounds, during pregnancy or lactation, or in malignant neoplasia. 
Patients on cyclosporine should probably receive only killed vaccines, and not be treated with 
ectoparasitic doses of avermectins. Cats should be checked for FIV, FeLV, and Toxoplasma infection 
prior to therapy. Cyclosporine is effective for allergic pruritus, eosinophilic plaques, and eosinophilic 
granulomas in cats.
TOPICAL THERAPY
Topicals can be useful adjuvants in the management of pruritus. Moisturizing shampoos 
(Hydra Pearls,® EVSCO/Vetoquinol; Epi-Soothe,® Virbac) and rinses (colloidal oatmeal) reduce 
pruritus by rehydrating stratum corneum and removing surface allergens, irritants, and 
microorganisms. Remember to use cool water. Added antipruritic effect can be attained with the local 
anesthetic pramoxine (Dermal-Soothe,® EVSCO/Vetoquinol; Relief,® DVM).
Table 1. Glucocorticoid Therapy in Cats
Species Drug Dose*
........  -
Frequency* Route
Cat Methyl predni sol one 20 mg/cat + SQ
Predni sol one/predni sone 2 mg/kg q24h PO
Triamcinolone 0.4 mg/kg q24h PO
Dexamethasone 0.2 mg/kg q24h PO
*These doses and frequencies are for induction. For maintenance, the lowest alternate evening dose 
achievable is indicated. In general, “safe” alternate-day doses of prednisone/prednisolone are <0.5 
mg/kg. Triamcinolone and dexamethasone are not safe for alternate-day therapy in dogs, but may be 
acceptable in cats.
+Can be given every 2 weeks for achieving remission (up to 4 times).. Chronically, no more 
frequently than every 3 months.
Table 2. Antihistamine Therapy in Cats"
! Drug Dose Frequency
Cetirizine 5 mg/cat ql2-24h
*Chlorpheniramine+ 2-4 mg/cat ql2h
*Clemastine 0.67 mg/cat q 12h
*Cyproheptadine+ 2 mg/cat ql2h
Diphenhydramine 0.5 mg/kg ql2h
Hydroxyzine 1-2 mg/kg ql2h
Oxatomide 10-30 mg/cat q 12h
*Dr. Scott’s favorites.
+Peer-reviewed publication(s) demonstrate efficacy.
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Table 3. Heterocyclic Antidepressant Therapy in Cats
Drug Dose Frequency
*Amitriptyline 5-10 mg/cat q24h
Buspirone 2.5 mg/cat ql2h
Clomipramine 1.25-2.5 mg/cat q24h
Fluoxetine 1 mg/kg q24h
*Dr. Scott’s favorite.
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I N F  L A M M  A  T O R Y  L I V E R  D I S E A S E  I N  C A  T S
Debra L. Zoran, DVM , PhD , D iplom ate A C  V IM  
Texas A & M  University
Diseases affecting the liver are a common clinical problem in cats. There are four major 
types of liver disease in cats: hepatic lipidosis, cholangiohepatitis complex, infectious hepatitis 
(e.g. FIP), and neoplastic liver disease (e.g. lymphoma). As with all diseases of the liver, 
histopathology is required for a definitive diagnosis, and this is the most important step in 
determining treatment and prognosis. Although there is no universally accepted classification of 
inflammatory liver disease in cats, classification based on histopathologic features is one method 
that has been used. In general, there are two distinct histopathologic features that are used to 
describe inflammatory liver diseases: cholangiohepatitis (acute and chronic forms, also termed 
suppurative and lymphoplasmacytic forms) and lymphocytic portal hepatitis. Acute 
cholangiohepatitis is characterized by infiltration with large numbers of neutrophils into portal 
areas and bile ducts, resulting in disruption (necrosis) of hepatocytes and ultimately infiltration 
of neutrophils into the hepatic lobules. This syndrome is believed to be secondary to ascending 
bacterial infection (although bacteria are not often cultured).
The second type of cholangiohepatitis is a chronic form, and is theorized to be a late 
stage of the acute disease. In this form there is a mixed inflammatory infiltrate present in the 
portal areas and bile ducts, but the unique feature is the presence of bile duct hypertrophy and 
portal fibrosis. This form of cholangiohepatitis is frequently associated with inflammatory 
bowel disease and pancreatitis, or the so-called triad disease. The relationship these 
inflammatory infiltrates have to one another is still unclear, however, there is no question the 
relationship exists. Finally, lymphocytic portal hepatitis is distinct from chronic 
cholangiohepatitis in that the lymphocytic infiltration affects only the portal areas, not bile ducts, 
and there are variable degrees of fibrosis and ductal hypertrophy present. Many older cats (82% 
in one study) have hepatic infiltrates that are characterized as portal hepatitis, and many of these 
cats are asymptomatic, so the true clinical significance of this change is not well understood. 
Nevertheless, once a diagnosis is obtained, the goal for treatment of cats with severe liver disease 
is to provide optimal nutritional and pharmacologic support to maximize liver function, 
minimize future liver damage or scarring, and to promote a high quality of life for as long as 
possible if the disease is not curable.
Clinical Features & Diagnosis
Inflammatory liver disease can present in cats with few external clinical signs other than 
inappetance or lethargy, or can cause severe illness resulting in development of ascites, icterus, 
hepatoencephalopathy, coagulopathy, and loss of ability to appropriately metabolize protein or 
carbohydrates. Thus, there is no single set of clinical signs or laboratory abnormalities that will 
define all liver disease patients. Nevertheless, there are some important clues that can help guide 
the clinician through to a definitive diagnosis.
Key Diagnostic Features
•  In addition to liver enzyme activites, there are 5 key parameters to assess in a cat with 
suspected liver disease: albumin, total bilirubin, glucose, BUN, and cholesterol -  all of 
these have important ties to liver function and be very useful clinical clues to the severity 
of the illness. Further liver function testing (e.g. bile acid testing) is not needed in cats
with hyperbilirubinemia not due to extra-hepatic causes, as this confirms the presence of 
liver dysfunction.
• Icterus may indicate liver disease, but the key is to remember that hyperbilirubinemia 
may occur due to PREHEPATIC (hemolytic), HEPATIC, or POSTHEPATIC (biliary 
tree, gall bladder, and common duct) causes. All three types o f cholangiohepatitis can be 
associated with icterus, so this is not a good sign to distinguish them.
•  Ascites can also indicate liver disease, but it too, can have prehepatic (cardiac), hepatic, 
or post-hepatic (portal hypertension, portal vein thrombosis, G1 disease). Further, 
leakage o f fluid into third spaces can be from leaky vessels (vasculitis), lack of colloid 
oncotic pressure (low albumin), or increased intravenous pressure (cardiovascular, 
thromboembolic disease). In general, ascites is a rare finding in cats with inflammatory 
liver diseases, as they are rarely reach the point of liver failure.
• In cats, the half life of both serum alkaline phosphatase and alanine aminotransferase 
enzymes are much shorter than in dogs, so any elevation of these enzymes should be 
considered significant. As in dogs, neither ALP or ALT are specific for liver disease or 
representative o f the degree o f liver damage or functionality; however, elevations o f these 
enzymes provide evidence or support for further evaluation.
• Serum gamma glutamyltransferase (GGT) is a more specific, and sensitive test of biliary 
tract disease in cats, and thus, is often increased in cats with cholangiohepatitis but is 
usually not increased in cats with idiopathic feline hepatic lipidosis.
• The liver is the major site of synthesis of most coagulation factors, coagulation inhibitors, 
and other essential elements of the clotting system, thus, it is highly advisable to assess a 
buccal mucosal bleeding time, prothrombin time, and platelet count prior to performing a 
liver aspirate or biopsy. However, a recent study showed that cats with significant liver 
disease and coagulopathy may still have normal prothrombin times, and in these cats the 
PIVKA test may be more reliable. Vitamin K therapy prior to surgery or biopsy is 
recommended in all cats with severe liver disease.
•  Analysis o f the liver via imaging is an important method of assessing liver size (e.g.
chronicity), liver echogenicity (e.g. circulation, biliary tree, infiltrative or space
occupying diseases), and the presence o f other abnormalities, such as masses, gallstones, 
bile duct obstruction, etc.
• Despite all o f these approaches, liver disease is defined and classified on the basis o f
histomorphologic appearance. In other words, biopsy is essential to defining the problem
and making an appropriate plan for treatment.
•  Whenever liver tissue is obtained for biopsy, additional tissue should be collected for 
culture, especially in cats with fever, acute onset of signs, or when acute (suppurative) 
cholangiohepatitis is suspected.
Wedge Liver Biopsy vs. Fine Needle Aspirate/Biopsy
Histologic evaluation of the liver is the most definitive method of diagnosing liver 
disease. This requires examination o f enough tissue to distinguish not only changes in 
hepatobiliary and vascular structures, but also the regional distribution o f any lesion, so that it 
can be better classified. Unfortunately, the invasive nature o f obtaining a sample, the danger of 
hemorrhage due to coagulopathies, the lack of universal availability of laparoscopic equipment 
and expertise, and the time required for sample submission and preparation all limit the routine 
use o f obtaining a surgical biopsy in clinical practice. For this reason, tissue aspiration or needle 
biopsy (using tru-cut or other similar needle biopsy instruments) to obtain tissue via ultrasound
guidance for cytologic examination are widely used alternatives. However, there are some 
significant issues regarding both o f these techniques that should be well understood.
Fine Needle Aspiration/Cytology
• Use an 18-22 g needle with a 12 ml syringe (with or without an extension set attached to 
the needle for better control)
• Expel contents of needle onto a glass slide, then gently place a second slide on top of the 
first to spread the cells into a monolayer (do not press! -  these cells are fragile and will 
often explode -  leaving the cytologist with a garnish to read)
• The sample is air dried, then stained with Diff-Quik or other similar Wright-Giemsa 
stain.
• This technique works well for diagnosis of diffuse homogeneous liver disorders that 
exfoliate well -  e.g. lymphosarcoma, hepatic lipidosis without other concurrent disorders
• However, if  lesions are not diffuse (e.g. cholangiohepatitis, certain neoplasms, nodular
disease, etc) or lobar in distribulation, the diagnosis may be missed or inaccurate.
Spring-triggered Needle Biopsies
• Have gained great acceptance with using ultrasound guidance due to being a rapid and 
relatively safe method of obtaining tissue for histopathology without laparotomy or 
laparoscopy.
• 18 g spring-triggered biopsy needles (e.g. tru-cut)(l mm biopsy chamber)
• No great advantage over needle aspiration for diffuse, homogeneous, exfoliative liver
diseases
• Same problems with missing the diagnosis as for aspiration -  plus, there is a slightly 
greater risk for bleeding following this procedure.
• In human medicine, as has been found in a recent study in veterinary medicine,
specimens obtained with an 18 g biopsy needle must be interpreted with caution for these 
reasons: 1) there is considerable variability in tissue involvement (independent of
ultrasound appearance), 2) ultrasonographic targeting can overlook areas having 
substantial pathology, 3) obtaining a few biopsy specimens from a single liver lobe can 
misrepresent the overall disease process.
• In addition, in 1/3 of cases in another study, needle biopsy specimens gave a false 
positive result (found evidence of liver disease, especially inflammation), when 
examination of wedge biopsy sections of the liver were normal.
• The morphologic diagnosis assigned to a needle biopsy specimen agrees with the 
definitive diagnosis only 50% of the time.
Wedge Biopsies (either Laparoscopic or Surgical)
• Greater morbidity due to anesthesia and surgical procedures, which may be unacceptable 
for some patients.
• With laparoscopy, there is minimal invasiveness, but maximum ability to obtain large 
wedge biopsies from multiple liver lobes, assess appropriate hemostasis, and biopsy 
regions that are grossly abnormal that may have been missed at US.
• Method o f choice for obtaining a definitive diagnosis in many liver disorders.
• Surgery is the method o f choice (required) if  one o f the following conditions exists: 
biliary decompression is required, cholelithiasis or biliary mucocele is present, removal
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of inspissated bile is needed, necrotizing cholecystitis is present or suspected, surgical 
removal of mass or lobe is needed.
Treatment of Hepatic Disease: Dietary Therapy
The key to appropriate dietary therapy in patients with chronic liver disease is to provide 
a diet that provides optimal nutrition for the cat while not increasing work load on the liver (e.g. 
protein metabolism). In addition, the ideal diet should provide additional nutritional support tor 
liver functions and special needs (e.g. added carnitine, arginine, zinc, and vitamins B complex, E 
& K), while reducing the amounts of substances that may contribute to liver dysfunction or signs 
o f failure (e.g. aromatic amino acids, methionine, sodium). One of the key’s to this therapy is 
reducing the amount and type of proteins that cause hyperammonemia and 
hepatoencephalopathy, while making sure that protein is available to meet the body’s needs 
(immune function, etc) and prevent further catabolism of muscle protein (this is especially 
important in cats). Further, carbohydrates must be available in a readily digestible form to 
decrease the need for glycogen breakdown and glucose synthesis, for which both processes may 
not be optimally functioning due to the liver disease. Finally, lipid metabolism (absorption, 
processing into bile acids, storage, etc) is also often compromised in patients with liver failure, 
thus, restriction of the amount of fat in the diet and providing fat soluble vitamins in water
soluble forms is often necessary.
One readily available commercial diet that will meet these needs is Hill’s 1/d (liver) diet. 
Other diets that may be used to feed cats with severe liver disease include other moderate to low 
protein diets designed for treatment of renal disease (e.g. H ill’s k/d, Purina’s NF, IVD Modified, 
or lam ’s Nutritional Kidney Formula). However, caution is advised with use of these diets, as 
the levels of protein may be too low or the type o f protein not appropriate for liver failure. In 
cats that do not have signs of hepatoencephalopathy, the highly digestible diets (e.g. Hill’s i/d, 
Purina’s EN or lam ’s low residue) may be completely acceptable.
Nutritional Support Keys:
• Place a feeding tube (either esophagostomy or PEG) as soon as possible in cats that are 
anorectic for > 3 days, or in cats with IHL, so that appropriate enteral nutritional support 
can be obtained.
• We are placing far more E tubes now than in the past -  they are faster, safe, require less 
technical equipment, and can be left in place for as long as needed to provide nutritional 
support.
•  Calculate nutritional needs and develop a feeding plan: start slow and work toward a 
feeding plan that the owner can manage.
• RER = resting energy requirement = 70(BWkg)°'75 or 30(BWkg) + 70 thus, an 11 lb (5 
ktz,) cat would need 220 kcal to meet their RER.
• a/d = 1 .5  kcal/ml of food unblended, other diets (1/d for example), have to be blenderized 
-  1 can food with 1 can water -  which makes them 0.6 kcal/ml
• To reduce nausea and vomiting, feeding should begin slowly (small meals ted often) -  
we recommend 4-6 meals per day at first, starting with */2 of the calculated RER the first 
day, then gradually increasing the amount each day.
• Ultimately, the goal is two reduce feedings to 2-3 meals per day, but this will depend on 
the cat. At full feed 3 times a day = 90 ml/feeding of a diet containing 1/kcal/ml. This 
amount of food must be administered very slowly and in some cats, may be too much at 
one sitting for the first few days or weeks.
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Antibiotic therapy is frequently recommended in the treatment of liver disease; however, 
they may or may not be indicated depending on the diagnosis. For example, in cats with 
suppurative cholangiohepatitis, antibiotic therapy is essential to appropriate therapy, while in 
cats with lymphoplasmacytic cholangiohepatitis, antibiotic therapy may not be warranted. 
Antibiotic choices should concentrate well in bile in cats with significant changes in the biliary 
system. However, the most important consideration is that they provide broad spectrum 
coverage for microbes typically present (e.g. anaerobic and gram negative G1 microflora). The 
most common isolates are E. coli, Enterococcus, Clostridium , and Klebsiella spp. Antibacterials 
that may be useful include metronidazole, clindamycin, enrofloxacin, azithromycin,and 
doxycycline. Because tetracycline may increase hepatic lipid accumulation, it should not be used 
in cats with liver disease. This effect has not been reported with doxycycline. 
Ampicillin/clavulonate and cephalosporins are very useful antibiotics for cholangiohepatitis but 
these drugs will not reach high concentrations in bile. If there is severe liver compromise and 
poor bile flow, the concentrations of drugs excreted by the biliary system may need to be 
decreased by 30-50%.
Anti-inflammatory/Immunosuppressive Therapy
The most common cellular infiltrate in chronic liver disease of cats is a lymphocytic 
plasmacytic cholangiohepatitis. Steroids have both anti-inflammatory and anti-fibrotic 
properties, and thus are the treatment of choice for this type of inflammatory response. The dose 
for anti-inflammatory therapy of liver disease is 1 mg/kg/day, but in severe disease, with fibrosis, 
immunosuppressive doses (2-4 mg/kg/day) must be used. Prednisolone may be preferred in 
cases with severe liver disease because the drug doesn’t require further hepatic metabolism to be 
effective (the true significance of this in cats is not known). The dose should be tapered to the 
lowest effective dose (maintains remission of clinical signs) after an initial treatment period of 2- 
4 weeks. In cats requiring long term therapy with steroids or in ones that don’t tolerate steroids 
(e.g. they have become diabetic), it may be necessary to add azathioprine to help control the 
progression and prevent fibrosis. Because cats are very susceptible to the neutropenic side 
effects of azathioprine, careful monitoring of blood counts are essential. Other drugs, such as 
cholchicine and zinc acetate, which are used in dogs to prevent fibrosis and hepatic scarring, 
have not been studied in cats. Zinc therapy must be used very cautiously, as excessive zinc 
supplementation can lead to acute, massive hemolysis.
Hepatoprotectants
Actigall (Ursodiol, Ursodeoxycholic acid, UDCA)
Ursodial is an unconjucated bile salt that has been used frequently dogs, cats and humans 
with cholestatic liver disease to improve bile flow, reduce bile sludging, prevent gallstones, and 
reduce the hepatocellular damage resulting from cholestasis. The recommended dose is 10 
mg/kg/day for cats. The mechanism by which UDCA increases bile flow is by promoting 
choleuresis through the process of cholehepatic shunting. In humans, UDCA has been found to 
be most helpful in patients with primary biliary cirrhosis; however, no controlled trials in dogs or 
cats have been conducted to assess its most effective uses. Nevertheless, some experimental and 
antecdotal evidence suggests that UDCA improves hepatic function in cats with chronic 
cholangiohepatitis, and it has no known severe side effects. Evidence in humans suggests that 
UDCA used alone is much less effective than polymodal therapy (with SAMe, milk thistle,
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Antimicrobial Therapy
vitamin E, etc), and this has been recommended in cats as well. Further, it should not be used to 
relieve suspected reduced bile flow in cats with gall bladder or common bile duct disease that is 
best dealt with surgically.
SAMe (S-adenosylmethionine, Denosyl)
SAMe is a naturally occurring molecule (nutriceutical) that is involved in the metabolism 
of methionine to homocysteine and glutathione. Glutathione is an essential cellular 
anti oxidant/free radical scavenger, and this is the mechanism for which SAMe is used - to reduce 
further oxidative damage to hepatocytes. Specifically, SAMe appears to increase hepatic and 
mitochondrial glutathione concentrations, improves organelle and cell redox states, and restores 
or preserves hepatic glutathione concentrations during oxidative stress. SAMe has been widely 
studied in humans and is recommended for use in chronic active or cirrhotic liver disease to slow 
the progression or onset of hepatic failure. In addition, SAMe has been shown to have anti­
inflammatory properties and promotes hepatocellular regeneration -  the mechanism ot which is 
not known. Recent studies o f SAMe (e.g. Denosyl) in dogs and cats , the drug appears to protect 
against oxidant injury (acetaminophen and other liver oxidant injury), may improve bile flow in 
cats, protect from bile induced injury to hepatocytes, and may inhibit hepatocyte apoptosis. One 
important thing to note about use of SAMe (and other nutriceuticals) is that not all products are 
the same. SAMe is available in two isomer forms (R,S and S,S), and only the S,S form is active. 
Some companies marketing SAMe are not cautious about the purity of their SAMe, and thus, the 
product may contain high percentages o f the R,S isomer (inactive). This information is not 
typically on the label and may be hard to find or is unknown. Denosyl (the veterinary product 
from Nutrimax Laboratories) has proven and documented the product’s purity, and as such, this 
is the only product currently recommended for use in cats. The recommended dose is 20 
mg/kg/day orally.
Milk Thistle (Silymarin)
Silymarin is the active extract of the milk thistle plant, which is a nutriceutical used‘for 
centuries to treat humans with liver disease. The important functions and hepatoprotective 
properties of silymarin include its role as an antioxidant and free-radical scavenger in the liver, 
it’s inhibition of hepatotoxin binding, its role in increasing glutathione concentrations, it serves 
as an iron chelator, and it is known to promote choleuresis. Whether or not these specific effects 
occur in cats is not known, but studies in rats and humans, and anecdotal reports in dogs suggest 
that it has a beneficial effect, and side effects are extremely low. The dose recommended is 4-8
mg/kg/day.
N u tr it io n a l S u p p le m en ta tio n
Vitamins E and C
There is ample evidence that chronic liver injury is partly due to oxidative damage to 
hepatocytes Further, there is also supporting evidence that antioxidant therapy may be beneficial 
in managing chronic liver diseases. One such beneficial supplement is vitamin E (d-alpha 
tocopherol) which has been shown to protect against oxidative damage from iron, copper, and 
bile acids. The dose o f vitamin E recommended for use in hepatic disease is 100-400 IU/cat q 24
hr. If the water soluble formulation of the vitamin is given, there is a greater chance that the 
vitamin will be adequately absorbed orally. Caution is advised in over-supplementation with 
vitamin E because of the potential for toxicity; however, this is less of a problem with this fat 
soluble vitamin than it is with vitamin A.
B vitamins (complex')
In anorectic cats with liver disease, supplementation with B vitamins may improve 
appetite and increase the availability of these essential vitamins (e.g. cobalamin, folate, thiamine) 
needed to improve healing, promote normal metabolism and improve energy utilization by cells). 
Measurement of cobalamin levels is indicated in cats with signs of GI disease to determine it 
cobalamin supplementation is needed. The dose of vitamin B complex is 0.5-1.0 ml/cat IV or 
SQ, or 5 ml/liter bag of fluids. Cobalamin supplementation is 250 ug/cat/week.
L-carnitine
There is good evidence in cats that L-camitine may protect against hepatic lipid 
accumulation, especially in obese cats that may already have some lipid metabolic disturbances. 
Carnitine is a nonessential amino acid that is vital in the transport of long chain fatty acids into 
the mitochondria for oxidation into energy (in the absence of carnitine, beta oxidation of fatty 
acids does not occur). Impaired energy formation leads to impaired fatty acid oxidation and urea 
cycle function -  both of which will lead to increase production of ammonia. Carnitine 
supplementation for cats with liver disease is recommended at 250 -  500 mg/day.
Other Considerations
In addition to all of the above dietary and pharmacologic treatments, cats with liver 
disease may have coagulation defects for which vitamin K therapy may be needed. Patients 
with severe liver failure may develop ascites due to hypoproteinemia for which diuretic therapy 
may be indicated, and they often require therapy to control signs of hypergastrinemia (e.g. 
vomiting, nausea, anorexia) which may include histamine-2 receptor antagonists or specific 
antiemetic therapy. In conclusion, management of chronic liver disease can be challenging, and 
require a variety of pharmacologic and dietary intervention strategies. To achieve optimal 
results, both the veterinary clinician and the owner must be willing and able to provide the 
intensive therapy and monitoring required to adjust to the patients changing needs. However, 
with appropriate management, most cats can return to fully functional lives for months or years 
to come.
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In veterinary and human medicine, renal function generally is held to be equivalent to 
glomerular filtration rate (GFR). We recognize that this is an oversimplification as the kidney 
has a wide variety of functions; disease processes can interfere with one function (e.g., urinary 
concentration or renin production) without significantly altering GFR. However, for clinical 
purposes the degree of renal injury and its clinical significance can best be judged by assessment 
of the degree o f decline of GFR. We generally use serum creatinine concentration to assess GFR 
in clinical patients.
SOURCE OF AZOTEMIA
Generally, azotemia may be pre-renal, renal, or post-renal in origin. Examples of 
prerenal dysfunction include systemic hypotension and dehydration. Examples of post-renal 
dysfunction include urinary tract obstruction and urinary bladder rupture. Regardless of the site 
of origin, renal dysfunction is characterized by the accumulation of nitrogenous waste, 
disordered electrolyte metabolism, and changes in body fluids status.
CKD is frequently present in patients presented for clinical therapy. The overall 
prevalence of renal disease in dogs and cats has been variously estimated at 0.5 percent to 2 
percent o f all animals. However, in animals presented to referral veterinary clinics, particularly 
older animals, the prevalence may be as high as 10 to 30 percent o f all patients.
STAGES OF FELINE CHRONIC KIDNEY DISEASE (fCKD)
fCKD is generally a progressive disease. Consequently, not all animals with fCKD 
should be managed similarly. One approach is to subdivide animals with chronic renal disease 
into four stages, as recommended by the International Renal Interest Society (IRIS; see Table 1).
Stage I: Non-azotemic fCKD
A primary renal disease is any process that damages the kidney. Examples would include 
bacterial infection, hereditary nephropathy, neoplasia, and hypertensive nephropathy. 
Unfortunately in veterinary practice we frequently identify the consequences of destruction of 
renal tissue but not the cause of the destruction because we miss the early stage where there is 
damage but adequate renal function. This stage, here referred to Non-azotemic fCKD is defined 
as the initial stage of this process where renal tissue is damaged by a primary disease process but 
compensatory renal responses mask both the injury and its effect on the clinical patient. The 
animal is not azotemic but may have some compromise of urinary concentrating ability. This 
stage can be rather devastating to the kidney: renal functional reserve provides that an animal 
with 75 percent destruction of renal mass generally has no observable clinical signs!
If chronic renal disease is identified in this early stage, the primary goal is diagnostic: 
identify the primary cause of renal injury and this is often achieved with a renal biopsy. It renal 
imaging studies suggest a disease is generalized then an ultrasound guided needle biopsy is 
appropriate. However, animals with in this stage with focal, multifocal, and/or unilateral renal
disease are best assessed by exploratory surgery and directed biopsies of both kidneys. An 
unfortunate error is occasionally made when one presumes that a kidney appearing grossly 
normal is unaffected by a microscopic disease process. Therapeutic concerns in this first stage of 
renal disease center upon identification of clinical manifestations of renal injury such as systemic 
hypertension or proteinuria. Further therapeutic concerns include therapy designed to slow the 
progression o f renal disease, such as dietary modification or the use of antihypertensive agents.
Stage II: Mild renal azotemic
The second stage of fCKD, herein referred to as mild renal azotemia, occurs when there 
is sufficient loss o f renal tissue such that azotemia is present without clinical signs. During this 
stage, progression of the disease process is an important consideration and therapy is generally 
focused upon delaying this rate of progression. The rate of progression is often slow in cats 
(months to years) but erratic and more rapid in dogs (weeks to months). Therapy in dogs and 
cats with renal insufficiency would center upon dietary modification and/or the administration of 
antihypertensive agents, with these efforts designed to slow the progression of the fCKD.
Stage III: Moderate renal azotemia
The third stage of fCKD, herein referred to as moderate renal azotemia, is a transition 
stage. During this stage, progression of the disease process is still an important but clinical signs 
of uremia are often present, intermittently at first. Therapy in cats in stage 111 would center upon 
dietary modification, administration of antihypertensive agents, and supportive (symptomatic)
care.
Stage IV: Severe renal azotemia
The fourth stage of renal disease is referred to as Severe Renal Azotemia. Animals in 
stage 4 fCKD often exhibit abnormalities of electrolyte balance and have markedly reduced 
ability to deal with changes in fluid and sodium intake. They may exhibit systemic hypertension. 
Poor appetite, nausea, and vomiting often lead to negative caloric and nitrogen balance causing 
loss o f depot fat stores and depletion of lean body mass. In this advanced stage ot renal disease, 
a nonregenerative, normocytic, normochromic anemia is often present and this complicates 
therapy." Animals with renal failure may have a subclinical compromise o f both the immune 
system and hemostatic mechanisms. In stage IV, therapy focuses upon minimization ot these 
clinical manifestations of uremia. While dietary therapy includes dietary protein and phosphorus 
restriction, it is often more important (and difficult) to assure adequate caloric intake.
Some of these complicating factors, such as electrolyte disorders and anemia, are readily 
identified by laboratory assessment of the patient. Other problems may be less readily apparent. 
For example, platelet function may be depressed in animals with renal failure, although this is a 
minor effect’and, by itself, is not usually clinically important. This effect of renal failure on 
platelet function can be important in animals where there is another pre-existing coagulation
disorder.
Systemic hypertension is often present in animals with stage IV or severe renal azotemia 
and BP should be assessed by appropriate direct or indirect measuring techniques to determine if 
hypertension is present and to plan accordingly. Animals with systemic hypertension (systolic 
BP>160 mmHg) are at risk for suffering an adverse event. The most common adverse events ot 
marked systemic hypertension (systolic BP > 180 mmHg or an acute rise of systolic BP of 30 
mmHg within 24 hours) include hypertensive retinopathy (intraocular hemorrhage, retinal 
edema and/or retinal detachment in cats and dogs) and hypertensive encephalopathy 
(progressive stupor, coma, and seizures in cats). Therapeutic agents that raise BP, such as fluid 
and electrolyte solutions, should be used judiciously in these animals. Cats in particular, are
susceptible to the development of hypertensive encephalopathy, caused by cerebral edema. 
Where observed, emergency therapy is appropriate. Agents to use in this setting include 
amlodipine (0.25 mg/kg given orally once daily), hydralazine (2 mg/kg given orally or 
parenterally every 8-12 hours), or both.
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Table 1: IRIS* Classification of Feline Chronic Kidney Disease (fCKD)
Stage I II III IV
Non-azotemic
fCKD
Mild renal 
azotemia
Moderate renal 
azotemia
Severe renal 
azotemia
Creatinine:
(pmol/L) < 140 140 to 250 251 to 440 >440
(mg/dl) <1.6 1.6 to 2.8 2.9 to 5.0 >5.0
*IRIS: International Renal Interest Society
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We now recognize that proteinuria is associated with increased risk of developing end- 
stage renal failure in cats and with an increased risk of mortality even in nonazotemic animals. 
Further, studies have shown that therapies that reduce the magnitude of proteinuria are often 
renoprotective.
Recent findings have suggested that renal protein leak is not only a marker of severity of 
renal disease but also potentially could be a cause of renal injury. While the role of this protein 
leak in producing renal damage has not been clearly established in cats, findings in cell culture 
studies and investigations of rodent models of renal failure raise our concerns for the importance 
of separately evaluating our patients for the presence or absence of proteinuria and for 
monitoring patients with proteinuria to determine its magnitude, location, persistence. We 
should investigate proteinuria in those cases where it is present and institute appropriate therapy, 
if  indicated. It is critical, however, that veterinary clinicians develop an enlightened approach to 
the diagnosis and management of proteinuria.
Proper management of proteinuria mandates two initial steps. First, a finding ot 
proteinuria should lead to characterization (confirmation by sulfosalicylic acid or Robert’s 
reagent or urine protein/creatinine ratio; quantification by the urine protein/creatinine ratio) and 
if confirmed, it should be categorized.
Categorizing Proteinuria - Prerenal Proteinuria
Prerenal proteinuria is caused by the presence of proteins in the plasma that are filtered 
through a normal glomerulus with normal permeability to macromolecules (i.e., permselectivity). 
These proteins may be normal proteins (e.g., hemoglobin) or abnormal proteins such as 
immunoglobulin light chains (e.g., Bence-Jones proteins)
Categorization of Proteinuria - Postrenal
Postrenal proteinuria is due to plasma proteins from hemorrhage or inflammation in the 
urinary tract (kidneys, ureters, bladder, urethra, and/or accessory sex glands). Many would also 
include extra-urinary losses such as from the accessory glands or genital tract as a postrenal 
cause of proteinuria..
Categorization of Proteinuria -  Three Types of Renal Proteinuria
Most, but not all, causes of renal proteinuria are abnormal. There are some functional 
causes of proteinuria (e.g., fever or exercise) that are transient, mild, and reversible and 
considered variants of normal.
Pathological renal proteinuria is due to a renal abnormality in protein handling. It may 
occur from increased leakage o f protein across the glomerulus (permselectivity defect causing 
ulomerular proteinuria) or abnormal tubular handling o f filtered protein (tubular proteinuria), or 
both. Tubular proteinuria occurs because small plasma proteins (<15,000 molecular weight) 
freely traverse the glomerular barrier. There are also small amounts of larger molecular weight 
proteins (e.g., albumin = 69,000 gm/mole) that are filtered through the normal filtration barrier. 
In a normal kidney, the tubules reabsorb practically all of this filtered protein. In some diseases 
(e.g., gentamicin nephrotoxicosis) the glomerulus is normal and permits filtering of only small 
molecular weight proteins and a minor amount of albumin. However, the diseased tubules are 
unable to metabolize these proteins and tubular proteinuria ensues.
Protein may also enter the tubular fluid from interstitial inflammation (e.g., 
pyelonephritis or renal neoplasia) and this is referred to as interstitial proteinuria.
Proteinuria in cats
Once proteinuria is identified and categorized, it is critical to ascertain whether or not it is 
persistent. Generally, this means assessing the urine protein/creatinine ratio on 3 occasions at 2 
week intervals. In cats with chronic kidney disease, urine protein/creatinine values > 0.4 in cats 
are associated with an increased risk of mortality. A benefit of angiotensin converting enzyme 
inhibitor therapy has been shown for cats with a ratio o f 1.0 or greater. Anti-proteinuric, 
renoprotective therapy is generally taken to be indicated in cats with kidney disease and a 
persistently elevated ratio which exceeds 0.5. In cats, this will initially be an angiotensin 
converting enzyme inhibitor (e.g., benazepril at 0.5 mg/kg once daily).
Results of recent studies suggest have heightened our concern about the importance of 
proteinuria in dogs and cats, as evidence suggests that persistent proteinuria is associated with 
progression o f chronic kidney disease (CKD) and worsened mortality rates, perhaps even in 
animals without CKD. In veterinary medicine, we have traditionally relied upon the urine 
dipstick and more recently, the urine protein-to-creatinine ratio, to identify and characterize 
proteinuria. Now there is a renewed focus on proteinuria and more specifically on 
microalbuminuria as a screening test for our patients. It is altogether fitting and proper that we
should do this.
It has long been known that in diabetic people, proteinuria is a hallmark ot impending 
nephropathy. Studies to quantify protein in the urine of diabetic people demonstrated that even 
small quantities o f albuminuria were predictive of subsequent renal disease. This small amount 
o f albuminuria (30-300 mg albumin in a 24-hour urine collection) was less than that observed in 
overt proteinuria (>300 mg/24 hrs) and it became known as microalbuminuria because it was a 
comparatively smaller (“micro”) amount of albumin observed in the urine. A 24-hour urine 
collection test to detect for the presence microalbuminuria test has been used tor decades as a 
screen in diabetic people. In this nomenclature, < 30mg albumin/day is normal in people, 30-300 
mg/day is defined as microalbuminuria, and >300mg/day is proteinuria.
While we often think of proteinuria originating from the glomerulus as a sign of kidney 
disease recently it has been shown that in people with endothelial dysfunction small amounts of 
albumin can leak through the glomeruli of an otherwise normal kidney, producing 
microalbuminuria. This led to a new hypothesis: generalized endothelial dysfunction is manifest 
in the renal microcirculation as glomerular capillary albumin leak, which the clinician 
(veterinarian and physician) can detect as the presence o f microaobuminuria. These consequent
small amounts of albumin may be detected only by sensitive tests, which may confirm the 
presence of microalbuminuria. Traditionally this would require a 24-hour urine collection as a 
screening test.
Tests for microalbuminuria became a focus in human medicine where microalbuminuria 
is an independent risk factor for death from cardiovascular disease and for the development of 
myocardial infarction and stroke in people with CKD. Indeed, these cardiovascular 
complications are more common end-points than uremic mortality for people with CKD. In the 
past decade it has become apparent that that microalbuminuria is a marker for fairly common 
renal and cardiovascular problems, including systemic hypertension, neoplasia, and generalized 
inflammatory conditions in people. As the need for a more clinically useful microalbuminuria 
test arose, measurement of the urine albumin/creatinine ratio (> 30 mg/gm is abnormal) or the 
use of albumin dipsticks became commonplace in people as a screening test for the presence of 
microalbuminuria.
Veterinary medicine has historically utilized the routine (traditional) urine dipstick as a 
screening tool for identifying proteinuria and employed the urine protein-to-creatinine ratio to 
provide semi-quantitative information about the magnitude of proteinuria in positive cases. This 
back-up test is required because the dipstick is only qualitative and is fraught with problems, 
particularly in specificity. There is now a commercially available albumin-detecting dipstick test 
(E.R.D.-Screen™ Urine Test, Heska, Ft. Collins, CO) which is more sensitive and specific than 
the routine urine dipstick and that could be used to confirm the presence of proteinuria in the 
face of a positive dipstick result. It is altogether fitting and proper that we should do this.
Critically, the traditional dipstick will generally detect urine albumin present at a 
concentration of >30 mg/dL, whereas the new albumin-specific dipstick can reportedly detect > 
1 mg/dL. Because this microalbuminuria is thus reportedly more sensitive than the traditional 
urine dipstick, it has been become possible to use this new dipstick as a test for the presence of 
microalbuminuria in dogs and cats. It can thus be employed as a screening test in dogs and cats, 
similar to the approach in people. By one method of classification in veterinary medicine, 
microalbuminuria is defined as a positive albumin-specific dipstick in the absence of a positive 
routine (traditional) urine dipstick. We could use this test to screen all dogs and cats for the 
presence of CKD or for the presence of endothelial dysfunction. Based on what we know today, 
we need to act cautiously in this regard as it is probably not altogether fitting and proper that we 
should do this.
First, transient microalbuminuria may be observed in a variety of transient conditions, 
some of which remain to be identified in dogs and cats. Persistent m icroalbuminuria  is an 
important clinical finding. In dogs and cats, persistent microalbuminuria is defined by the 
ACVIM Proteinuria Consensus Panel as microalbuminuria found repeatedly in > 3 specimens 
obtained > 2 weeks apart which cannot be attributed to a postrenal cause. Persistent 
microalbuminuria is often due to altered glomerular perm selectivity (CKD or endothelial 
dysfunction); but impaired tubular handling of the small amounts of albumin that traverses the 
normal glomerular filtration barrier can also cause microalbuminuria. There is no clinically 
applicable way to reliably determine the source of microalbuminuria (glomerular vs. tubular). 
Nonetheless, progressive increases in magnitude of microalbuminuria are likely to indicate 
significant renal injury.
Since persistent microalbuminuria  may be a marker of either CKD or endothelial 
dysfunction in do^s and cats, a microalbuminuria screening test may lead to discovery of a
3
treatable underlying CKD or an inflammatory, metabolic, or neoplastic condition in an 
apparently healthy animal.
Urine testing that for the presence o f microalbuminuria should be considered for the 
following circumstances: animals with chronic illnesses that may be complicated by proteinuric 
nephropathies (e.g., systemic lupus), screening apparently healthy dogs that are > 6 years old and 
cats that are > 8 years old, animals with confirmed or suspected systemic hypertension, screening 
dogs or cats to detect possible onset of a hereditary nephropathy as early as possible.
Much remains to be learned about this exciting and novel approach that utilizes of the 
presence o f small amounts of protein in the urine as a potentially valuable early marker of CKD 
and other conditions of clinical importance in dogs and cats. As veterinarians, we should be 
open to adopting this approach as we carefully scrutinize the literature for developing new 
information. It is altogether fitting and proper that we should do this.
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Renal insufficiency and hyperthyroidism are relatively common conditions of older cats. 
Hyperthyroidism is the most common endocrinopathy of older cats and chronic renal failure 
(CRF) is diagnosed commonly in older cats, especially those older than 10 years of age. 
Chronic renal failure is estimated to be the number two cause of death in domestic cats of 
the USA (Morris Animal Foundation Survey). It can be difficult to accurately diagnose cats 
with chronic renal failure, hyperthyroidism, or both conditions as there are many 
overlapping clinical signs (weight loss, polydipsia, polyuria, dilute urine). It is likely that 
hyperthyroidism is underdiagnosed in cats with chronic renal failure since nearly half ot cats 
with CRF and hyperthyroidism will have a normal T4 level on a single measurement. In cats 
with a palpable thyroid nodule and CRF or chronic renal disease, definitive diagnosis of 
hyperthyroidism may require thyroid scintigraphy or T3-suppression testing.
The relationship between the development of hyperthyroidism as a consequence of renal 
insufficiency has not been explored. The possibility that hyperthyroidism causes chronic 
renal disease in some cats has received little attention. Most attention has focused on the 
simultaneous occurrence of renal insufficiency and hyperthyroidism in a population of cats 
under consideration for treatment of hyperthyroidism. It has been observed that a population 
of hyperthyroid cats develop azotemia or display a worsening of azotemia following therapy 
that induces euthyroidism. Hyperthyroidism potentially could induce renal failure through 
effects of systemic hypertension, intraglomerular hypertension/hyperfiltration (Scott: Has 
this been looked at by you  or others ?), atypical hyperparathyroidism, and hypercalciuria.
Thyroid hormones exert major effects on renal functions. Normal cats undergo increased 
GFR and RBF and decreased BUN and serum creatinine following administration of 
exogenous thyroxine administration for 30 days (Adams 1997). Groups of cats with 
hyperthyroidism often have increased GFR compared to normal cats. Plasma iohexol 
clearance in 12 hyperthyroid cats was 3.83±1.82 ml/min/kg (N = 1j ) compared to normal 
cats at 1.83 ± 0.56 ml/min/kg (n = 10) (Becker 2000). Similar results were found when GFR 
was determined using DTPA clearance nuclear medicine (2.51±0.69 ml/min/kg in 13 
hyperthyroid cats vs. 2.02 ± 0.27 ml/min/kg in 11 normal cats) (Graves 1994). 
Hyperthyroidism is known to result in dilute urine and polyuria with polydipsia. This effect 
is likely due to increased RBF and medullary solute washout, though a direct etfect on the 
collecting tubules and ADH receptor interaction cannot be excluded. Psychogenic 
mechanisms also cannot be excluded. Hyperthyroidism is known to result in hypercalciuria 
in other species due to enhanced bone calcium mobilization; this effect may have some role 
in the development of polyuria as well as a possible role in creating chronic renal damage by 
excessive exposure of renal tissue to calcium. Most cats with hyperthyroidism also have 
increased systemic blood pressure, which could injure renal tissue. Hyperparathyroidism 
was noted in 77% of 30 cats with untreated hyperthyroidism; the magnitude of increased 
PTH levels was very large in some instances (Barber 1996). The reversibility of 
hyperparathyroidism following correction of hyperthyroidism has not been reported. Though 
serum creatinine (and calcium) was lower in this population ot hyperthyroid and
hyperparathyroid cats, the possibility of renal secondary hyperparathyroidism cannot be 
excluded (renal disease may still exist and not be detected).
Hyperthyroid cats (n = 12) decreased GFR (iohexol clearance) from 3.83±1.82 to 2.02 ±
0.81 4 to 6 weeks following treatment with methimazole (Becker 2000). Two of these 12 
cats developed overt azotemia following treatment in this same study though as a group 
increases in BUN or serum creatinine did not achieve statistical significance. Twenty-two 
hyperthyroid cats treated with radioiodine experienced no change in GFR, BUN, or 
creatinine 6 days following treatment (T4 was decreased), but BUN and creatinine were 
significantly increased at 30 days (T4 was also further lowered) (Adams 1997). No cats with 
a GFR > 2.25 ml/min/kg developed post treatment renal failure in this same study. Thirteen 
of 15 cats with GFR < 2.25 ml/min/kg were in renal failure 30 days following radioiodine 
treatment (2/15 that failed to suppress T4 did not develop azotemia); 9 of these 15 were 
azotemic prior to treatment; the others had normal parameters initially (Adams 1997). GFR 
(DTPA nuclear clearance) decreased from 2.51 ± 0.69 ml/min/kg to 1.40 ± 0.41 ml/min/kg 
30 days following bilateral thyroidectomy in 13 cats (Graves 1994) while creatinine 
increased from 1.26±0.34 to 2.05±0.60 and BUN increased from 26.62±6.83 to 34.92±8.95.
Azotemia prior to treatment o f hyperthyroidism was detected in as many as 41% of cats and 
in 59% of cats 30 days post treatment in one study (Adams 1997). Twenty-three percent 
developed azotemia for the first time following treatment in the same study. Mean serum 
creatinine and BUN increased at 30 and 90 days post-treatment in 58 cats treated by surgery, 
methimazole, or radioiodine; there were no differences in the magnitude of increase by 
treatment group (Dibartola 1996). Nine of these 58 cats had increased serum creatinine 
concentration prior to treatment. Two o f 12( Becker 2000) and 2 of 13 (Graves 1994) cats 
developed overt azotemia following treatment with methimazole or bilateral thyroidectomy 
respectively. Based on results o f these three studies, it appears that an estimate for the 
development o f de novo azotemia following treatment for hyperthyroidism in cats is from 
15-23%. Some increase in serum creatinine concentration is expected following the 
development o f euthyroidism due to increased muscle mass (origin of creatinine), though 
decreased GFR certainly contributes to increased serum creatinine concentration. It is likely 
that lessening the degree of hyperthyroidism results in decreased RBF and GFR that 
unmasks azotemia in cats with marginal renal function prior to therapy.
Serum creatinine concentration in cats with reduced lean muscle mass may seriously 
underestimate any degree of excretory renal dysfunction since less creatinine will be 
qenerated from these muscles. Reduced muscle mass is common in advanced 
hyperthyroidism and in those with chronic renal disease. In these instances, serum creatinine 
will be lower than it would be if muscle mass were greater. It is wise to ask the question 
“What would the serum creatinine likely be if muscle mass were normal 9 It is possible that 
cats with upper range “normal” serum creatinine concentration and poor muscle condition 
have underlying renal disease. It is especially important in these situations to critically 
evaluate the results of urinalysis. If the urinary specific gravity is less than 1.040 increased 
suspicion for primary renal disease is warranted. Measurement ot GFR using nuclear 
medicine clearance methods or iohexol clearance is recommended in cats whose renal 
function is uncertain prior to permanently inducing a euthyroid from hyperthyroid state. 
Those cats with lower values for GFR are at risk to develop overt azotemia and possibly 
clinical signs o f CRF following conversion to euthyroidism. Rarely, some cats without pre­
existing azotemia and with urinary specific gravity greater than 1.040 prior to treatment
develop CRF within 6 months of treatment for hyperthyroidism -  whether this is a 
consequence of the conversion to euthyroidism in unclear.
Should cats with overt azotemia and hyperthyroidism be treated for hyperthyroidism 9 Some 
endocrinologists and nuclear medicine specialists advocate so. It is likely that many of these 
cats will increase their level of azotemia following treatments that result in euthyroidism or 
hypothyroidism. In some cats this increase in creatinine will be mild, while other cats will 
experience large increases in serum creatinine. If clinical signs related to hyperthyroidism 
are severe, at attempt at treatment is warranted. We recommend screening cats with obvious 
azotemia and those suspected of renal disease with a methimazole challenge. Some had 
advocated that all cats should have methimazole challenge testing whether or not renal 
disease is suspected or not as the best standard of care. Methimazole treatment provides a 
reversible means of inducing euthyroidism and observing what happens to the level of renal 
function. An initial dose of 2.5 mg BID is given for 2 weeks and then serum biochemistry is 
repeated to evaluate renal function and T4 levels. If renal function is stable, the dose is 
gradually increased every two weeks as needed until T4 levels have entered the normal 
range if renal function remains stable. The dose can be increased to 2.5 mg TID, then 5 mg 
BID, and 5 mg TID if needed. Methimazole is discontinued if renal function deteriorates 
during the methimazole challenge. If renal function remains stable, then long-term 
methimazole can be considered for therapy or more-definitive treatment of hyperthyroidism 
provided by 1-131 treatment or surgery. The definition of "stable" renal function is arbitrary 
and in our hospital means that the creatinine increased less than 2.0 mg/dl in those without 
initial azotemia and less than 1.0 mg/dl in those with obvious azotemia.
Supplementation with thyroxine should be considered for those cats with worsening signs of 
renal disease or excretory renal function that become hypothyroid following bilateral 
thyroidectomy or radioiodine treatment. About 9% of cats develop low T-4 values post I- 
131 treatment. Anecdotal evidence suggests that excretory renal function can be supported 
in some post-treatment hypothyroid cats when supplemental thyroxine is supplied. As a 
compromise, it may be desirable to titrate the dose of methimazole in cats with marginal 
renal function in such a way as to partially control the hyperthyroidism without decreasing 
GFR too much. Other treatments to control cardiac effects of uncontrolled hyperthyroidism 
may be warranted (beta blockers such as atenolol).
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High systemic arterial blood pressure is commonly observed in dogs and cats with 
chronic kidney disease. In veterinary medicine, systemic hypertension has been associated with 
ocular pathology, progression of CKD, neurological complications, and cardiovascular changes. 
As our understanding of the prevalence and consequences of systemic hypertension moves 
forward, so must our ability to diagnose and manage this problem.
Rationale for Diagnosis and Treatment
Systemic hypertension can damage a variety of tissues. The kidney is susceptible to 
hypertensive injury. There is a clear association between ocular injury and marked systemic 
hypertension in dogs and cats. Findings associated with hypertensive injury include hemorrhage 
within the retina, vitreous, or anterior chamber; retinal detachment and atrophy; retinal edema; 
perivasculitis; retinal vessel tortuosity; and glaucoma.
Because the heart is working against an increased arterial pressure (i.e., afterload), left 
ventricular hypertrophy and secondary valvular insufficiency may be observed. Tachycardia is not 
a common finding with hypertension although some primary diseases that lead to secondary 
hypertension, such as hyperthyroidism, may also lead to elevated heart rate. Left ventricular 
hypertrophy may regress with anti hypertensive treatment.
Figure 1: Thresholds for adverse effects of systemic hypertension:
Signs consistent with cerebrovascular hemorrhage (head tilt, depression, seizures) have 
been seen clinically in cats with uncontrolled hypertension, and are often associated with a poor 
prognosis. However, cats suffering from systemic hypertension (systolic blood pressure >160 
mmHg) occasionally develop a syndrome of progressive stupor, head pressing, and/or seizures 
which rapidly resolves with effective antihypertensive therapy. This syndrome is probably due to 
cerebral edema caused by high intracapillary hydrostatic pressure which develops once the 
systemic arterial pressure exceeds the autoregulatory range.
Importance of Measurement of Blood Pressure
A diagnosis of systemic hypertension is based upon determination of systemic arterial blood 
pressure. Further, the indiscriminate use o f antihypertensive therapy in the absence o f reliable 
values for systemic arterial blood pressure is inappropriate. This is highlighted by the fact that 
antihypertensive agents may induce a variety of side-effects, including dehydration and volume 
depletion; systemic hypotension leading to weakness, syncope, and renal dysfunction; or 
hypokalemia and associated clinical signs. Therefore, reliable measurement of blood pressure is 
required to establish a diagnosis of systemic hypertension and the efficacy o f antihypertensive 
therapy must be judged upon the basis o f blood pressure measurements.
Which patients to assess?
Blood pressure could be measured in patients with each of the following groups of 
patients: (i) all patients, (ii) patients with clinical signs referable to hypertensive injury, or (iii) 
patients at risk for developing systemic hypertension. While it is possible to measure blood 
pressure in all clinical patients, currently there is not sufficient rationale to do so in cats. Many 
hypertensive cats present with signs attributable to high systemic arterial blood pressure, such as 
blindness, hyphema, seizures, ataxia, or sudden collapse (signs compatible with cerebral vascular 
hemorrhage, edema, or stroke), or labored breathing (signs related to heart failure). It is clear that 
measurement o f systemic arterial blood pressure should be an integral part o f the management of 
these patients.
If the veterinarian only measures blood pressure in those animals suspected o f having 
complications secondary to hypertensive injury, the opportunity for early identification of 
hypertension and intervention is lost. Thus, patients with no evidence of hypertensive injury but 
know to be at risk for the development o f systemic hypertension also should be assessed. As 
primary or essential hypertension is apparently rare in cats, systemic hypertension in veterinary 
practice will nearly always be associated with another disease or condition. Population surveys 
suggest that most cats with chronic kidney disease and cats with hyperthyroidism are hypertensive. 
In addition to routine screening of patients with chronic kidney disease, hyperthyroidism, and 
advancing age, conditions in which blood pressure measurements are indicated include obesity, 
hyperadrenocorticism (endogenous or exogenous), diabetes mellitus, mineralocorticoid-secreting 
tumor, and pheochromocytoma.
Measurement Method
Doppler principle devices are useful in cats. The oscillometric devices have utility in cats 
when applied above the elbow, but this approach has not been critically evaluated by comparison 
to a gold standard. At the present time, on the basis of studies in conscious animals, devices using 
the Doppler principle are recommended for use in cats.
Cuff choice and placement
An oversized cuff may give erroneously low recordings; an undersized cuff a falsely high 
reading. Indirect blood pressure measurement studies should employ a cuff width that measures
30-40% of the circumference of the limb. If the ideal cuff width is midway between two available 
sizes, the larger cuff should be used, since it will theoretically produce the least error.
The cuff may be placed around the brachial, median, cranial tibial, or medial coccygeal 
arteries. Generally, for the Doppler technique the cuff is placed over the median artery and the 
transducer is placed between the carpal and metacarpal pad. Clipping of hair and application of 
acoustic gel at the site of transducer placement may enhance the signal. For the oscillometric 
technique, the median artery and coccygeal artery provided more reliable values than other sites in 
our studies.
The cuff should be placed at the level of the aortic valve. If not, a compensation can be 
made for gravitational effect with a 1.0 mmHg rise in blood pressure expected for each 1.3 cm of 
vertical distance between the level of the cuff and the level of the aortic valve.
A n x iety  and  th e w h ite  coa t effec t
The visit to the veterinary clinic, hospitalization, presence in a strange environment, restraint in 
the examination room, clipper noise and vibration, cuff placement, cuff inflation, and other 
unusual stimuli in the setting of a veterinary hospital may induce anxiety in an animal during blood 
pressure measurement. As a consequence, a falsely elevated value for blood pressure may be 
obtained secondary to catecholamine release associated with this anxiety. Unfortunately, the 
magnitude of this effect varies widely between animals and between visits in the same animal. 
The extent of this effect may be minimized by doing the following: (a) obtain blood pressure 
measurements prior to a physical examination or other manipulations to which the animal may 
object, (b) perform all measurements in a quiet room utilizing a calm and reassuring manner, (c) 
allow the animal to acclimate to its surroundings for at least 5 minutes before obtaining blood 
pressure measurements.
C o n sc io u s A n im al B lood  P ressu re  M ea su rem en t P roced ure:
1. Environment: Quiet, away from other animals, owner present (generally)
2. Equilibration Time: 10 minutes (quiet and undisturbed)
3. Device: Oscillometric or Doppler principle device; both devices if available. For comparative
purposes, the same device should be used each time in an individual animal.
4. Cuff width: 30-40% of limb circumference. The cuff width should be noted in the medical
record for future reference.
5. Site of cuff placement: median artery for Doppler device; coccygeal artery also okay for
oscillometric device. Mid-humerus in cats for oscillometry. For comparative purposes, the 
same site for cuff placement should be used each time in an individual animal. And recorded 
in the medical record.
6. Personnel: Same individual (preferably a technician) performs all blood pressure measurements
following a standard protocol
7. Patient: should be calm, motionless
8. Measurements: 3 - 5 consistent measurements from cuff placement 1
Repeat as necessary if results from cuff sites do not agree within 20%
Average all values to obtain blood pressure estimate 
Note site of cuff placement for future reference
9. Unless it is an emergency (e.g., retinal detachment plus sever hypertension) a diagnosis of
systemic hypertension should be established only after at least 2 repeat measurement sessions 
confirm the elevated blood pressure. These sessions should be separated by at least 30 
minutes.
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Which animals to treat?
There is a clear association between end-organ injury and systemic hypertension in cats.
We currently recommend the following classification system upon which to base treatment. { 
Animals with confirmed hypertension should be treated while the animals should be treated only if 
there is evidence o f ongoing hypertensive end-organ injury. Effective treatment of animals in 
stage II should be immediate. Those in Stage I can be further evaluated at the discretion of the 
clinician on the basis o f the clinical findings. Frequent re-evaluations are appropriate in all of the 
higher blood pressure classes.
Table 1: A Blood Pressure Classification System for Cats
Risk Category Systolic Diastolic Risk of Future TOD
I <150 <95 M inim a1
II 150-159 95-99 M ild
III 160-179 100-119 M oderate
IV >180 >120 Severe
Therapeutic Goal
It is usually not possible to restore blood pressure to normal values when treating a 
hypertensive animal. It should be the veterinarian’s goal to lower the blood pressure to within 25- 
50 mmHg of the normal ranges for blood pressure, ideally lowering pressure (systolic/diastolic) to 
< 160mmHg/l OOmmHg.
Therapy
An inhibitor o f angiotensin converting enzyme (e.g., 0.5 mg enalapril or benazepril/kg 
orally every 12-24 hours) may lower blood pressure. In cats, though, the role of the renin- 
angiotensin system in the maintenance of systemic hypertension has been questioned and though 
less effective in cats, a higher dosage (1-2 mg enalapril/kg orally every 24 hours) may prove 
efficacious in hypertensive cats. The co-administration of an ACE inhibitor and a calcium channel 
antagonist (see below) may prove effective when monotherapy is not sufficient in lowering blood 
pressure.
Some drugs classified as calcium channel antagonists reduce total peripheral resistance, 
leading to a decrease in blood pressure. Amlodipine besylate, a long-acting dihydropyridine 
calcium antagonist, has been used successfully as a single agent in hypertensive cats at a dosage of
0.625 mg/cat orally every 24 hours. Larger cats (>4 kg) often require 1.125 mg orally every 24 
hours. Blood pressure decreases significantly during amlodipine treatment, and significant adverse 
effects (i.e., azotemia, hypokalemia, weight loss) are not frequently identified. Because 4$ 
amlodipine has a slow onset of action, adverse effects such as hypotension and loss of appetite are 
usually avoided.
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F E L I N E  O B E S I T Y :  
O V E R N U T R I T I O N  O R  W R O N G  N U T R I T I O N ?
Debra L. Zoran, DVM , PhD, D iplom ate A C V IM  
Texas A & M  University
“The smallest feline is a masterpiece” -  so said Leonardo Da Vinci. Cats are truly unique 
in almost every aspect of their existence, from their behavior to their biochemistry. It is those 
differences that bring us to our topic o f discussion, the nutritional peculiarities of the feline. In 
particular, this review is not going to simply be an accounting of their metabolic differences, but 
more importantly, an overview of how not taking into account these differences lead to disease 
(hepatic lipidosis), disability (obesity), and possibly, nutritional problems for our sick feline 
patients.
Feline Nutrition
Cats are obligate carnivores. This statement is news to no one, and yet many don’t 
recognize the importance of that statement. While cats can use carbohydrates (CHO) as a source 
of metabolic energy, they have no requirement for them (nor do dogs for that matter). But, more 
importantly, because cats evolved consuming prey (e.g. high protein, low to moderate fat, 
minimal carbohydrate), they are metabolically adapted for higher protein metabolism and lower 
CHO utilization. What does that mean metabolically and nutritionally? There are a number of 
specific metabolic and biochemical differences in feline physiology that are important. For those 
who are interested in the specific details of these metabolic and physiologic differences in the 
nutritional biochemistry of cats, the reader is referred to a recent review of this subject1. To 
summarize the major differences, cats have obligate and daily needs for additional protein, 
specific requirements for certain amino acids (e.g. taurine, arginine), increased requirements for 
many B vitamins, and reduced ability to digest, absorb and metabolize carbohydrates. This paper 
will discuss several important medical problems in cats that may be directly linked to, or may be 
specifically managed by, dietary manipulation.
Cats and Nutrition: Key Facts
• Cats have an obligate need for protein and amino acids in their daily diet because they are 
unable to down regulate their urea cycle or transaminases (protein conversion to energy) 
as other species can in times of starvation
• Cats utilize protein for energy, even in the face of large amounts of CHO in the diet 
(there is no “down-regulation” or protein sparing when CHO are plentiful in the diet as 
with other species)
• Taurine, arginine, methionine, cysteine, and possibly carnitine requirements for cats are 
greater than non-carnivores
• Arachidonic acid is also an essential fatty acid in cats (it is not in dogs), and is found only 
in fats from animal tissue
• Cats require vitamin A and D to be present in the active form in their diet as they are 
unable to synthesize adequate amounts from other dietary precursors (e.g. carotenoids or 
vitamin D precursors in skin)
• Cats have an increased need for many B vitamins in their diet (e.g. thiamin, pyridoxine, 
niacin, pantothenic acid) as they have greater metabolic needs for these vitamins and 
cannot synthesize or get them from other sources.
•  Salivary amylase is absent in cats, and they have greatly reduced levels of intestinal and 
pancreatic amylases -  so CHO digestion is much less efficient.
• Cats have fewer disaccharidases and other brush border enzymes in their small intestine 
designed to digest and absorb starches.
•  The small intestine of cats is much shorter than that of an equally sized omnivore -  
longer G1 tracts are necessary for handling of complex carbohydrates.
• Cats have greatly reduced activities o f hepatic enzymes (e.g. glucokinase) designed to 
convert a post prandial glucose load to glycogen and thus are less able to handle this 
glucose load.
• There are no fructokinases in cats -  they are unable to utilize fructose and other simple 
sugars.
Feline Obesity
While figures vary, recent studies indicate that greater than 35% of cats in the United 
States are overweight or obese. There are a large number of factors that contribute to this 
problem, including sex (intact vs. neutered, male vs. female), age, activity (indoor vs. outdoor), 
and feeding style (meal feeding vs. free choice). Nevertheless, obesity is a significant 
contributor to morbidity in middle aged to older cats. Further, “it is much harder to take it off, 
than it is to put it on” -  as we are all very aware. One factor that is increasingly being 
considered, both in the development o f and treatment o f obesity, is the role of CHO in diet. 
Because o f the metabolic requirement for cats to utilize protein as an energy source, C-HO in the 
diet that are not immediately used for energy (e.g. via exercise or other utilization for energy) 
will be stored as fat. Traditional weight loss plans include feeding an energy restricted (e.g. low 
fat, high CHO, high fiber) diet. However, while these diets may result in weight loss, they do so 
to the detriment o f lean body mass. Successful weight loss requires loss o f  adipose tissue as well 
as maintenance o f lean body mass, as lean body mass is the driver o f basal energy metabolism 
(loss o f lean body mass is a major contributor to weight regain as appetite is not reduced and 
satiety not reached). Several recent studies have evaluated use o f a high protein, low CHO diet 
(protein 45% or higher) for weight loss in cats, and in those studies, all cats lost weight, but 
maintained lean body mass. Importantly, high protein, low carbohydrate diets not only result in 
sustained weight loss in these cats, but also in normalization o f appetite (reduced urge to eat 
constantly because they are satiated). Because dry foods must be extruded (i.e. made into a 
biscuit), CHO are required in the cooking process, and thus, the best commercial diets for 
achieving a high protein, low CHO profile are canned (e.g. kitten or growth) foods. However, 
there are now prescription diets formulated with a high protein/low CHO profile that are 
designated for weight management or, as we will talk about next, control o f diabetes mellitus.
Calculating calories. Most indoor cats do not need more than their resting energy requirement 
(RER) to meet their daily nutritional requirements. Cats that are very obese may need to reduce 
their intake by 20-40% (or 60-80% of RER) to lose weight. RER = 70(BWkg)°7:1 or if  the cat is > 
2kg: 30(BWkg) + 70. Thus, if  a 5 kg cat needs 220 kcal for RER, but is still obese, the intake 
must be reduced by 20%  (200 kcal/day) or 40% (160-180 kcal/day). EXAMPLE: Hill’s m/d = 
165 kcal/can, while Hill’s m/d dry = 485 kcal/cup -  thus, it is much more difficult to reduce 
calories using the dry food.
Key Points: The commercially available diets lowest in CHO are canned foods. The best high 
protein/low CHO diets are canned kitten foods or new diabetes diets (Hill’s m/d, Purina DM, 
Purina OM). Most cats should be fed some (50% is a starting point) canned food as part of their 
diet -  both to reduce the CHO in their diet, but also to better control calories (dry foods are very
calorie dense), and to increase the amount of water consumed daily. An important follow up 
point to remember about all diets is that calories count. You cannot free choice feed cats -  even 
with high protein, low carb diets -  because if they consume too many calories (and the diabetes 
diets are very calorie dense) they will remain obese. Also, calorie control and feeding canned 
foods must be started when they are kittens, as they will not learn to accept canned food (many 
adult cats won’t eat canned food because they were never introduced to it as kittens). This is not 
only important for diet selection now, but if  later in life the cat requires a canned prescription 
diet for a specific problem (e.g. kidney disease or urinary disease), they will more readily accept 
it if they already eat some canned food.
Feline Diabetes Mellitus
Approximately 65% of all diabetic cats fall into the category of Type II diabetes (obese, 
but may be transient, insulin or non-insulin dependent). This is in contrast to the disease in dogs, 
where the overwhelming majority o f cases are Type I (insulin dependent) diabetes. Dietary 
recommendations for years (which were extrapolated from human and canine recommendations) 
have been to feed these affected cats with diets high in complex CHO (e.g. high fiber diets). 
However, with our awareness of the role of diet in management of the problem of obesity, as 
well as some of the dietary issues that confound treatment of feline diabetes, these 
recommendations have been appropriately challenged. Recent studies have shown that high- 
protein, low-CHO diets are beneficial in the management of diabetes in cats, resulting in a 
greater than 50% reduction in the amount of insulin in 8 of 9 cats in one study. In another study, 
complete cessation of the insulin requirement occurred in a third of the cats. Other studies have 
recently shown that, contrary to what is observed in dogs, fiber containing diets do not alter 
glucose tolerance (an important reason for feeding high fiber diets in diabetic dogs and people). 
Another benefit of high protein/low CHO diets is that there is a reduction in post-prandial 
hyperglycemia (fewer CHO in diet to lead to a smaller post-prandial surge) and, this results in a 
concurrent reduction in hyperglycemia induced glucose toxicity.
Key points: The best commercially available diets for diabetic cats are high protein/low CHO 
canned diets (e.g. Hill’s m/d or Purina DM, Purina OM, or canned kitten foods). For cats that 
won’t eat canned foods, dry formulas that are high protein/low CHO include Purina DM, Purina 
OM, and Hill’s m/d
Feline Hepatic Lipidosis
Idiopathic hepatic lipidosis (IHL) is a common hepatobiliary problem in cats that stop 
eating, especially in cats that are obese or undergoing stress or illness. However, recent studies 
suggest IHL is the result of a combination of factors: excessive peripheral lipid mobilization 
(due to high catecholamine release from stress or illness), and subsequent development of 
nutritional deficiencies that compromise the formation of lipoproteins and the mobilization of 
hepatic triglycerides. The individual nutrients that may be involved include taurine, carnitine, 
arginine, threonine, citrulline, choline and cobalamin. However, the key to treatment of IHL 
remains feeding affected cats, usually through a feeding tube (esophagostomy or PEG tube) until 
their metabolism normalizes. Feeding a high quality, moderate to high protein diet for 2-6 
weeks, or until the cat begins to eat again, is the most important aspect of treatment. This cannot 
be over-stated: the key to treatment is for the cat to receive adequate protein and fat calories via 
tube feeding to correct the nutritional imbalance that has been created. Force feeding cats is not 
appropriate for treatment of this disease for several reasons: 1) the disease will require
nutritional support for 2-4 weeks in most cats to overcome the metabolic disturbance, 2) it is 
very difficult to achieve the daily caloric requirement by force feeding, and 3) force feeding cats, 
can lead to food aversion and additional stress.
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Key points. Most cats with hepatic lipidosis need a high calorie, high protein diet such as Hill’s 
a/d, Eukanuba Maximum calorie, or other recovery diet. If  the cat has severe liver failure and fl
cannot tolerate high protein diets, use o f H ill’s 1/d (liver diet) or one o f the canned renal failure 
diets is an acceptable alternative.
Juvenile Feline Diarrhea
There are a few factors to consider in the development of diarrhea in kittens, but dietary 
causes are important. First, a few facts, it is believed (with the published information that we 
have) that cats have much higher concentrations o f bacteria in their small intestine, compared to 
dogs and people. The reason for the increased intestinal microflora in cats is not known, but 
along with their shorter overall intestinal length (compared to dogs), the presence of increased 
numbers o f bacteria may serve to enhance digestion o f proteins and fats, both of which are 
higher in normal feline diets. Conversely, diets higher in CHO and fiber (especially soluble 
fibers) may predispose cats to intolerance, changes in bacterial flora numbers or species, or result 
in osmotic overload. This problem may become prominent when kittens are switched from milk 
or canned foods to dry food (because of the high CHO in dry foods). The alterations in bacterial 
populations or species are believed to lead to the development of diarrhea.
Key point. In young cats with diarrhea, or cats with intermittent vomiting or diarrhea that may 
be a result o f dietary intolerance, feeding diets high in protein and low in CHO, along with 
antibiotic therapy, may resolve the problem.
Feline Inflammatory Bowel Disease
Feline inflammatory bowel disease (JBD) is an idiopathic, inflammatory disease of the 4|j 
intestinal tract for which dietary and immunosuppressive/anti-inflammatory therapy seems to 
control, but for which we still have no clear understanding of its cause or perpetuation. A wide 
variety o f possible causes have also been investigated in humans with IBD, but current research 
is focused on the role of bacteria in the development and progression of the aberrant immune 
response that occurs in humans. This hypothesis may also be important in the pathogenesis of 
feline IBD as well, especially owing to the fact that cats often respond when combinations of 
metronidazole and steroids are used together. Further supportive evidence for a specific role of 
bacteria in the development o f feline IBD is lacking, but several aspects o f feline digestion and 
feline diets are suggestive of a possible role for microbes in the disease (see above). Diets higher 
in CHO and fiber (especially soluble fibers) may predispose cats to intolerance, changes in 
bacterial flora numbers or species, or result in osmotic overload. It is the alterations in bacterial 
populations or species that is believed to lead to the abnormal intestinal inflammatory response 
in humans with IBD, and may also be important in feline IBD as well. Dietary therapy may be 
appropriate for prevention of feline IBD, but once the disease has been initiated, these diets may 
not be sufficient to control the aberrant immune response. In fact, increased protein may result 
in an increased exposure of the gut immune system to these proteins resulting in further 
sensitization and inflammation. Nevertheless, this merits addition consideration and research as 
we continue to seek answers to perplexing issue.
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